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The 6-hydrazinonicotinyl group, known as HYNIC, is an attractive bifunctional coupling 
agent for preparing 99mTc-labeled peptides and proteins for medical imaging. Peptides are 
useful for imaging disease states such as cancer and inflammation because they take 
advantage of a distinct cellular target, such as a receptor, being present on the cell. Receptors 
are often over expressed on tumour cells. Peptides will bind to their receptors with high 
specificity and affinity. There is a recognized need to create well-defined polymer probes for 
in vivo and clinical PET and SPECT imaging to guide the development of new generation 
polymer therapeutics.  In general the amount of radionuclide used in radiopharmaceuticals is 
small, so attaching the radionuclide to a polymer ensures that the radionuclide will be highly 
concentrated in the radiopharmaceutical. The number of binding sites is increased with the 
copolymer making it a viable choice for radiolabelling applications. The chances of 
successfully imaging the point of interest are therefore increased.  
This thesis presents the synthesis of various HYNIC analogues that are capable of chelating 
technetium-99m in order to be attached to an amino acid and incorporated into a peptide 
sequence via solid phase peptide synthesis (SPPS) to image site-specific targets.  While 6-
HYNIC has been widely used, 2-HYNIC has not, and as such both of these were used in the 





NMR, FT-IR and melting point data was obtained for comparison with literature.  A number 
of derivatives were successfully synthesised and purified with the aim of binding these to 
copolymer chains. 
This work also presents the synthesis of a bifunctional copolymer (POEGMA-co-PAMA) 
which is biocompatible and can be attached to a HYNIC group and subsequently a peptide. 
This copolymer was synthesised using a controlled living radical polymerisation technique 
called Reversible Addition Fragmentation chain Transfer (RAFT).  This technique was 
chosen due to its ability to synthesise polymers with predetermined molecular weights of 
complex architectures whilst maintaining control over polydispersity.  Copolymers of varying 
compositions were synthesised and analysed by GPC and NMR.  This method (once 
optimised) would allow for the copolymer to be labelled with technetium-99 for SPECT, 
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Chapter 1- Introduction 
 
1.1 Molecular Imaging 
  
Modern day imaging techniques enable researchers to study molecular events in 
living subjects giving a wide range of data from simple planar anatomical 
information, to three-dimensional functional information.  According to Weissleder 
and Mahmood, "Molecular imaging can be broadly defined as the in vivo 
characterization and measurement of biologic processes at the cellular and 
molecular level.  In contradistinction to "classical" diagnostic imaging, it sets forth 
to probe the molecular abnormalities that are the basis of disease rather than to 
image the end effects of these molecular alterations.”.1 Molecular imaging provides 
in vivo information about proteins, genes, molecules, stem cells; thus mechanisms 
related to biological processes and diseases can be studied, with significant benefits, 
compared to in vitro and ex vivo studies.  Unlike other imaging modalities such as 
Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and 
Ultrasonography (US), nuclear medicine procedures are capable of mapping 
physiological function and metabolic activity and therefore give more specific 
information about the organ function and dysfunction.  The mapping of the 
radiopharmaceutical distribution in vivo provides images of functional morphology 
of organs in a non-invasive manner and plays an important role in the diagnosis of 
many common diseases associated with the malfunctioning of organs in the body as 
well as in the detection of certain type of cancers.  Radioisotope imaging uses 
radiation emanating from radionuclides in tracer quantity inside the subject.
2
 The 
widespread utilization and growing demands for these techniques are directly 




The main steps in molecular imaging with radioisotopes are: (i) design of molecules 
that can target specific receptors; (ii) attachment of radioisotopes that emit photons 
(for single-photon emission computed tomography, SPECT) or positrons (for 
2 
 
positron emission tomography, PET) without changing the biological properties of 




SPECT and PET are the two imaging modalities used in nuclear medicine.  Both of 
these modalities offer a non-invasive method to determine the concentration of 
specific molecules in the human body, and are sensitive enough to visualise 
interactions between physiological targets and ligands.
4, 8, 9
 
Molecular imaging is not however, limited to SPECT and PET.  The introduction of 
contrast agents allow functional information to be obtained even by using 
Computerized Tomography (CT), Ultrasound (US), Magnetic Resonance Imaging 
(MRI) and the various Optical Imaging techniques.  CT and MRI provide 
considerable anatomical information about the location and the extent of tumours as 
well as morphological information and potential metastases.
10, 11
 US images provide 
information about local and regional morphology with blood flow.  PET and SPECT 
map the location and concentration of radio-labelled compounds.  As well as giving 
the precise location, size, shape, and viability of the tumour, PET and SPECT 
provide information about the molecular makeup of the tumour and its metabolic 
activity.
11
 These imaging modalities can provide quantitative information with 











The application of radiolabelled peptides, peptide-hormones and proteins for 
diagnostic imaging and radiotherapy of cancers is a major aspect of nuclear 
medicine.
13, 14
 Radiolabelling is the chemical reaction during which a radionuclide is 
incorporated into the desired molecule.  A radionuclide is an isotope that undergoes 
radioactive decay; any element with an excess of either neutrons or protons in the 
nucleus is unstable and tends toward radioactive decay, with an emission of energy 
that can be measured with a detector.  The processes of radioactive decay include 
beta particle emission, electron capture, isomeric transition, and positron emission.  
These radiolabelled compounds, known as radiopharmaceuticals, are used in low 
concentrations and, as such, have minimal pharmacological effect.
15
  Among all the 
radionuclides being produced around the world, only a few combine the favourable 
characteristics of physical decay with desirable biological characteristics to become a 
useful medical radioisotope for molecular imaging.
16
 
Currently there are over a hundred radiopharmaceuticals, developed using either 
reactor or cyclotron produced radioisotopes, which are used for the diagnosis of 
several common diseases and the therapy of a few selected diseases, including 
cancer.
3
 Currently in nuclear medicine, almost 95% of radiopharmaceuticals are used 
for diagnostic purposes, while only 5% are used for therapeutic purposes.
15
 This 
work focuses on the use of radiopharmaceuticals for molecular imaging and as such 
only these will be discussed in detail, however, it is worth noting that the same 
radiolabelling techniques used for imaging can be used for radiotherapy too.
17, 18
 
There are several methods for radiolabelling including: isotope exchange; 
introduction of a foreign label; labelling with a bifunctional chelating agent (BFCA); 
biosynthesis; recoil labelling; and excitation labelling.
15
 Two of the more popular 
strategies for radiolabelling involve incorporating the radiotracer into the 
4 
 
biomolecule, and using a bifunctional chelator (BFC) to attach the radiotracer.
19
 
Molecular imaging with radionuclides relies to a large extent on the formation of 
bioconjugates with metallic radionuclides using BFCs, which are molecules that bind 
covalently to the targeting molecule and chelate the radiometal, thus coupling the 




1.2.2 Properties of Radiopharmaceuticals 
 
Radiopharmaceuticals must have a number of desirable and interrelated properties in 
order to be successful.  They will have short effective half-lives (no longer than the 
time necessary to complete the study)
15
 and favourable decay in order to keep the 
dose to the patient as low as possible.  Also, the daughter nuclei should not present 
any additional radiological hazard.  Radionuclides which decay by γ-ray emission 
are preferable for use in diagnostic radiopharmaceuticals as α and β particles cause 
more radiation damage to the tissue.  For therapy however, α and β emitters are 
useful as they provide effective radiation damage to abnormal cells.
15
 Furthermore, 
the metal complex (if used) must be thermodynamically stable to give high yields 
during production and specific activity of 100% is preferable.  The 
radiopharmaceutical must be kinetically stable in order to remain intact long enough 
in vivo to locate the target, and it must have high affinity for its target.
22
 
Lipophilicity, size and total charge are some factors that have an effect on 
biodistribution.
23
 Lipophilic compounds may diffuse across membranes like the 
blood/brain barrier, while the charge may help them accumulate inside the target 
tissue.  Hydrophilic compounds tend to show rapid renal excretion.  Lipophilic 




Target-specific radiopharmaceuticals consist of a moiety, such as an antibody, 
peptide or low molecular-weight ligand which is linked to an appropriate 
radionuclide.
9
 Ideally these radiopharmaceuticals are designed to locate cancerous 
5 
 
tumours, even if their location in the body is unknown, while producing minimal 
radiation damage to normal tissues.
25
 
The radiolabelling of amino acids and progressing from this, peptides, has been the 
natural progression of targeted radiopharmaceuticals over the last three decades.
26
 
The small compounds often possess higher target-to-background ratios and faster 
blood clearance than the previously favoured proteins and monoclonal antibodies.
27
 
Target-specific delivery of radioactive peptides, both for molecular imaging and 
therapy, is increasingly considered a promising strategy,
9
 and peptide-based 
radiopharmaceuticals represent by far the largest group of tumour-targeted imaging 
agents currently in use.
28
 
Well established solid-phase peptide synthesis allows reproducible preparation of a 
variety of peptides with accurate chemical structures, which can be modulated to 
optimize affinity and specificity for the target, metabolic stability and 
pharmacokinetics.
4
 Peptides are useful for imaging disease states such as cancer and 
inflammation because they take advantage of a distinct cellular target, such as a 
receptor, being present on the cell.  Peptides will bind to their receptors with high 
specificity and affinity.
29
 Another advantage of peptides is their tolerance towards 
the modifications necessary for their labelling with different radionuclides.   
For radiometallation, for example, the most explored approach makes use of a BFC 





1.2.3 Bifunctional Chelating Agents 
 
If radiometals are used as the radiation source, the labelling reaction is often 
performed through chelation.
28
 The majority of diagnostic radiopharmaceuticals 
currently available in nuclear medicine use radiometal complexes or target-specific 
biomolecules labelled with metallic radionuclides.
21, 28
 The biomolecules are 
generally derivatised with a suitable metal chelating group that provides stable 
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chelation of the radiometal.  In general, a radiopharmaceutical containing a 
bifunctional chelating agent (BFCA) consists of the following parts: a targeting 
molecule, a bifunctional chelator (BFC), a radionuclide, and a linker.
21, 30
 The 
targeting molecule is a carrier of the radionuclide to the receptor site in vivo.  The 
radionuclide serves as the radiation source.  The BFC, covalently attached to the 
targeting molecule, functions as the coordinator of the radionuclide.  The linker, 
although not always necessary, acts as a spacer residue, which separates the targeting 
molecule from the chelating agent.  The BFCA is covalently attached to functional 




The choice of BFC is determined by the nature and oxidation state of the radiometal; 
different radiometals require BFCs with different donor atoms and chelator 
structures.
21
 The ideal BFCA should (i) coordinate a metal ion with a high yield, (ii) 
form metal complexes with both high thermodynamic stability and in vivo kinetic 




Hydrazine derivatives, such as 6-hydrazinopyridine-3-carboxylic acid (HYNIC), 
have been used routinely as BFCAs in nuclear medicine to label peptides and other 
biomolecules with technetium-99m for SPECT.
33
 HYNIC has also been used for 
labelling peptides and other biomolecules with fluorine-18 for PET.
34, 35
 HYNIC is 
an attractive BFC because of its monodenticity that allows for a variety of different 
coligands leading to  different biodistributions.
36
 Tricine and glucoheptonate are 
examples of coligands which allow easy modification of hydrophilicity and 
pharmacokinetics of technetium-99m labelled biomolecules.
21
 In addition, high 








HYNIC can be attached to the peptide via the amino acid side chains or the N/C 
termini.
39
 This is done post SPPS using standard conjugation techniques.  
Conjugation is usually via a primary amine or cystine 'handle' placed at the end of 
the peptide.  The advantages are that a number of conjugation methods may be 
performed on the same batch of peptide.  However, if there is more than one primary 
amine or the peptide requires a disulfide bond, losses in purification can occur as 






1.3 Positron Emission Tomography (PET) 
 
Positron Emission Tomography (PET) is used to monitor the concentration and 
movement of a positron emitting isotope in living tissue.
41
 PET is a powerful, non-
invasive molecular imaging technique which offers picomolar sensitivity and 
provides functional information on physiological, biochemical and pharmacological 
processes in living subjects.
42
 PET requires a tracer that is labelled with a positron-
emitting radionuclide which can be quantified in vivo by the detection of the gamma 
rays formed as a result of the annihilation of the positrons emitted.
42
 
A positron is annihilated in a distance of 1–4mm from each emission point and two 
opposite travelling photons are produced.  The detector needs to be able to 
simultaneously detect those two photons, and a reconstruction algorithm is necessary 
to obtain the three-dimensional distribution for radiopharmaceuticals concentration.  
The collision of an emitted positron with a nearby electron produces two gamma 
rays that are separated by 180°.  Two scintillation detectors that are separated by 
180° transmit a coincident signal when they are achieved simultaneously.  The 
photon energy that is absorbed by the detectors is re-emitted as visible light and 
detected by photomultiplier tubes.  The light signal is converted into an electrical 
current, which is proportional to the incident photon energy.  The registered events 
are reconstructed into a three dimensional image representing the spatial distribution 
of the radioactive source in the studied subject.
6, 43
 
PET offers significantly improved spatial resolution and sensitivity (by 2-3 orders of 
magnitude) when compared with SPECT
28
, and allows the performance of 
tomographic dynamic studies, something that is not possible with clinical SPECT 
equipment (with the exception of a few prototypes) 
6, 44
 In addition, the natural 
occurrence of PET isotopes in biologically active molecules provides for a less 
challenging task of synthesizing physiologically useful tracers in PET.
45
 The main 
limitation of PET, when compared to SPECT, is the use of short-life isotopes (see 
table 1.1), which increases overall cost, as well as the number of applications that 
can be imaged with PET isotopes.
6
 Nevertheless, the short half-lives of radionuclides 
9 
 
used in PET effectively allow for increased detection sensitivity over a given period 
of time.  This is because short-life isotopes can be injected in higher activities to the 
patient without posing any additional radiation damage to the patient (since overall 
accumulation over time remains the same) thus generating increased detectable 
radiation over a shorter time.
45
 The combination of high resolution and sensitivity 
and the ability to carry out dynamic tomographic studies leads to a number of 
dedicated PET scanners. 
 
1.3.1 PET Radionuclides 
 
A PET radiopharmaceutical consists of two components; a molecular structure 
(vehicle, ligand) and a positron emitting radionuclide.
46
 A linker may also be 
necessary to form a stable connection between the two components.  The molecular 
structure component defines pharmacokinetics and pharmacodynamics; the 
biological characteristics and biochemical interactions within the living organism.  
These molecules must provide a high degree of specificity and selectivity towards 
the target site.  The positron emitting radionuclide provides a detectable signal 
enabling coincidence measurements of annihilation radiation within a PET scanner.
47
 
The choice of the PET radionuclide is imposed by its physical and chemical 
characteristics, availability, and the timescale of the studied biological process.
42
 
Positron emission is exclusively a property of neutron deficient nuclides.
48
 
The choice of a radionuclide could depend on its physical half-life, which should not 
only allow the chemical incorporation (radiolabelling reaction) of the radionuclide 
into the target compound, but also match the biological half-life of a corresponding 




If the tracers need to be transported from the radiolabelling sites to imaging sites, or 
if a relatively lengthy labelling procedure is required, it may not be possible to use 
short lived isotopes such as carbon-11.  Due to the very short half-life of oxygen-15 
10 
 
and nitrogen-14 (see table 1.1), the tracers prepared are usually only in the chemical 
forms produced in a cyclotron target, or other derivatives that were obtained by 
instant high yield reactions.
42
 Other factors for isotope selection may include the 
conditions for radiolabelling, specific activity, and radionuclide production.
49
 
Specific activity is important in the preparation of radioisotopes, particularly in PET 
where the radionuclide is incorporated into a radiotracer which is used to probe some 
physiological process in which very small amounts of the biomolecule are being 
used.
50
 PET is essentially a tracer method and the goal is to probe physiological 
processes without disturbing the process.  If the amount of radiotracer is very small 
in comparison to the amount of the native compound or its competitor, then the 
process will be minimally disturbed.
51
 Specific activity is normally expressed in 
terms of the amount of radioactivity per mole of compound.   
The positron-emitting radionuclides must be made in the targets, and then converted 
to a precursor, either in the target or immediately after exiting the target.  The 
precursor is then converted into the molecule of interest.
50
 
There are four positron-emitting radioisotopes which are used more often than 
others.  These are fluorine-18, carbon-11, nitrogen-13 and oxygen-15.  The reason 
that they are most commonly used is that they can be easily substituted directly onto 
the biomolecules.  Carbon-11, nitrogen-13 and oxygen-15 are the 'elements of life';
50
 
the building blocks of the biochemicals that regulate biochemical processes.
52
 
Substitution of carbon-11 for carbon-12 does not significantly alter the reaction time 
or mechanism of a molecule.  A similar situation exists for nitrogen-18 and oxygen-
15.  Fluorine-18 can often be substituted for a hydroxy group on a molecule or 
placed in a position where its presence does not significantly alter the biological 










Table 1.1: Short-lived PET radionuclides with half-lives and nuclear reaction for 
production. 
 
Radionuclide Half-life (minutes) Nuclear Reaction 
Carbon-11 20.4 
14N (p, α) 11C 
Nitrogen-13 9.96 
16O (p, α) 13N 
Oxygen-15 2.07 
15









1.3.1.1 Radiolabelling with Fluorine-18 
 
Fluorine-18 is the most commonly used radionuclide for routine diagnosis with 
PET.
53, 54
 Fluorine-18 has a half-life of 110 minutes, low β+ energy, and is easy to 
produce.
55





F represents the ideal radionuclide for PET imaging.  
Due to its low positron energy it has a short positron linear range in tissue (max.  
2.3mm), allowing for optimum resolution images in PET.
56
 Furthermore, the 
relatively long half-life (in comparison, for example, to carbon-11, nitrogen-13 and 
oxygen-15) allows for syntheses of fluorine-18 labelled radiopharmaceuticals; 
transportation over reasonable distances; and imaging procedures to be extended 
over a few hours. 
12 
 
In order to make use of the desirable properties offered by fluorine-18, researchers 
have sought to develop radiochemical syntheses that are rapid, high yielding, 
chemoselective, and do not require deprotection steps.  However, the production of 
18
F-labelled tracers poses several challenges; ‘true’ or isotopic labelling is limited to 
molecules with a fluorine atom;
53
 however there are no naturally occurring fluorine-
containing compounds in the body and fluorine-containing biomolecules are often 
not suitable substrates in normal metabolic pathways as they can act as enzyme 
inhibitors.
57
 Other radionuclides such as oxygen-15, nitrogen-13, and carbon-11 are 
able to give isotopic labelling because the elements carbon, nitrogen and oxygen are 
all common in nature.  Therefore the radiolabelled tracers are indistinguishable from 
the stable isotope equivalent molecules.   This is not the case for fluorine-18; instead 
fluorine-18 is most commonly used by replacing hydrogen in organic molecules.
54, 58
 
This significantly affects the chemical and biochemical properties of the molecule 
(e.g.  distribution and metabolism).   
Fluorine-18 is usually produced as fluorine gas ([
18
F]F) by irradiating gas targets in 
the 
20
Ne(d, α)18F or 18O(p, n)18F reactions, or as aqueous ionic fluoride ([18F]F−) by 




F reaction.  The use of F2 as a 





There are various chemical reactions to incorporate the fluorine-18 isotope into 
target molecules but broadly speaking, labelling with fluorine-18 is either done by 
electrophilic substitution, using [¹⁸ F]F gas, or nucleophilic substitution, using the 
[¹⁸ F] fluoride ion.50 Both of these methods yield unwanted radioactive and non-
radioactive by-products that must be removed from the desired product by HPLC. 
Fluorination via electrophilic substitution is carrier added (c.a) using [¹⁸ F]F gas, 
(which is produced using a neon target containing around 0.1% 
19
F) where only one 
of the fluorine atoms in the [¹⁸ F]F gas produced will be incorporated into the target 
molecule.
59
 The use of electrophilic fluorination reactions is therefore not ideal as 
the maximum achievable radiochemical yield is only 50%.
50
 The electrophilic route 
also leads to low specific radioactivity due to the fact that carrier fluorine gas has to 
be added in order to recover the radiolabelled gas from the surface of the target 
walls.  Specific activities typical for electrophilic fluorinations are around 
13 
 
0.4GBq/μmol whereas nucleophilic fluorinations yield specific activities in the range 
of 50-500GBq/μmol.60 
Nucleophilic substitution is the most common route for labelling compounds with 
fluorine-18.
55
 This method offers high specific radioactivity and can be both direct 
and indirect.
61, 62
 The nucleophilic substitution (via SN2 mechanism) is based on non-
carrier added (n.c.a) [¹⁸ F] fluoride.54  The n.c.a [¹⁸ F] fluoride is obtained in the 
irradiated target water which renders the ion poorly reactive; fluorine-18 forms 
hydrogen bonds which decrease its nucleophilicity.  Therefore the labelling reactions 
take place under polar, aprotic conditions;
58
 this produces highly reactive fluorine-
18.  Anhydrous acetonitrile, dimethylsulfoxide and dimethylformamide are 
commonly used solvents for labelling.  Anion exchange resins are then used to 
separate [¹⁸ F] fluoride and recover oxygen-18 enriched target water.  The last of the 
water is removed by azeotropic distillation under a stream of nitrogen and thermal 
drying at temperatures of between 80-110°C.
52, 63
 
Fluorine-18 has been used to label many different biomolecules from small 
monomeric molecules to peptides, proteins, and oligonucleotides.
64-66
 The reason for 
labelling peptides is that they are specific so will be taken up selectively in tissues 
due to the presence of a specific receptor for a particular peptide.  In addition, the 
short biological half-life of many peptides matches the half-life of 
18
F.  Peptides can 




Anhydrous electrophilic [¹⁸ F]F is not used for labelling peptides.  This is because its 
chemical lability is not appropriate for the mild, aqueous conditions generally 
required, and because its specific reactivity is too low.
68
 Mild conditions are required 
as the high temperatures and strong bases that are used for radiofluorination destroy 






1.4 Single Photon Emission Computed Tomography (SPECT) 
 
Single Photon Emission Computed Tomography (SPECT) is a widely used and 
highly sophisticated method of molecular imaging.
70
 SPECT is a diagnostic imaging 
technique in which tomographs of a radionuclide distribution are generated from 
gamma photons detected at numerous positions about the distribution.
2
 SPECT relies 
on emission of a single gamma photon with enough energy (>100 keV) to escape 
from the body and be detected.  After injection of the radionuclide into the patient, 
these gamma photons are released from target areas.  The photons are captured on a 




SPECT is based on the idea that a radiopharmaceutical is injected into the body and 
concentrates in an organ or structure of interest.  SPECT can image endogenous 
ligands such as peptides, antibodies, hormones and selectins, which can be labelled 
with technetium (technetium-99m) or other isotopes.
6
 Due to their size, those 
molecules diffuse slowly into tissue and have slow clearance from blood, which can 
be of the order of hours or even days.  The half-life of the commonly used SPECT 
isotopes allows their imaging and makes possible imaging of slow processes such as 
cell division, infection and inflammatory processes and therapeutic 
radiopharmaceuticals.  The use of long-life isotopes make SPECT affordable for a 
number of research institutions.
6
 SPECT also has the unique ability to probe two or 
more molecular pathways simultaneously by detecting isotopes with different 




SPECT is more widely used then PET, in part, because the synthesis of SPECT 
radiopharmaceuticals based on technetium-99m are produced in ‘kit’ form.  The 
result of this is that the labelling procedure is simple and quick and can be carried 
out by a technician rather than a radiochemist.  The technetium-99m (as 
pertechnetate ion) is added to a pre-prepared, sterile mixture of labelling precursors 
and additives.  No final purification is necessary before injection into the patient.  
15 
 




Another reason that SPECT is more widely used than PET is that technetium-99m is 
produced by generators that are present in all hospitals where SPECT is carried out, 
whereas fluorine-18 must be made by a cyclotron.  Cyclotrons are too big and 
expensive for most hospitals to own, meaning fluorine-18 must often be produced in 
a different location to where it is used, causing problems with loss due to decay of 




1.4.1 SPECT Radionuclides  
 
The ideal SPECT radionuclide should; be highly stable in vivo; exhibit excellent 
tissue penetration; have high affinity for the target structure; have specific uptake and 
retention in the target cells; have rapid clearance from non-targeted tissues and 
organs; and be easy to prepare.
28
 Furthermore, SPECT radionuclides must either 
present; isomeric transition decay that emit gamma rays; or electron capture decay 
that emit x-rays and or gamma rays (in the range of 70-250keV).
72
 The gamma 
emission must be strong enough to penetrate the body barrier and detectable by 
SPECT camera systems.
73
 These characteristics are important so as to avoid 
unnecessary radiation dose burden to the patient as well as high background signals 









Table 1.2: SPECT radionuclides with half-lives and mode of decay. 
 
  
Radionuclide Half-life Mode of Decay 
Technetium-99m 6.0 hours IT (100%) 
Iodine-123  13.2 hours EC (100%) 
Indium-111 2.8 days EC (100%) 
Gallium-67 3.3 days EC (100%) 
17 
 
1.4.1.1 Radiolabelling with Technetium-99m 
 
Technetium-99m is the most widely used radioisotope in diagnostic nuclear 
medicine, it is estimated that over 80% of the diagnostic nuclear medicine studies 
carried out annually are done with technetium-99m.
3, 21
 The parent radionuclide 
molybdenum-99 can be prepared in abundant quantities by the fission of uranium-
235 in a nuclear reactor with a fission yield of about 6%.
3




Tc generator is ideal for use with SPECT as it decays to technetium-99m 
with emission of gamma photons with an ideal energy of 140 keV.
74
 These photons 
are emitted in high abundance.  The half-life of 6 hours is long enough for extended 
procedure to be carried out, but short enough to minimise the radiation dose to the 
patient - radiation from the low concentrations used for imaging is relatively 
harmless.
21, 50
 Technetium has no stable isotope and is a synthetic element.
75
 The 'm' 
in the name technetium-99m stands for metastable nuclear isotope.
76
 It does not 
change into another element upon decay.  The rapid blood clearance and the fast 
tumour accumulation of small peptides allow for the use of shorter-lived 




 In routine medical practice, due to its 
ideal properties for SPECT and the widespread use of this imaging technique, 
technetium-99m is still the radionuclide of choice. 
Despite the rise of PET and the growing availability of fluorine-18 as a radiolabel for 
PET, most widely used radiopharmaceuticals are labelled with technetium-99m.
38
 
Labelling biomolecules with technetium-99m using HYNIC as the chelator differs 
from other BFCs, as technetium binds to the hydrazino moiety forming a Tc-N 
bond.
21, 78
 To stabilise the molecule, co-ligands are required.  Babich and Fischman 
first reported that the nature of the co-ligand has a significant influence on the 




 Since then, a number of co-ligands have been 
described, among them tricine, aminocarboxylates, and ternary ligand systems using 
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Chapter 2 - Syntheses of HYNIC Analogues 
2.1 Introduction to HYNIC 
The first example using HYNIC (6-hydrazinonicotinic acid) as a bifunctional 
chelating agent (BFCA) for the synthesis of a radiopharmaceutical was the labelling 
of human polyclonal immunoglobin G (IgG) with technetium-99m and indium-111 
by Abrams and co-workers in 1990.
1
 Since then, HYNIC or 6-hydrazinonicotinic 
acid has been used routinely as a bifunctional chelating agent in nuclear medicine to 
label peptides and other biomolecules with technetium-99m for SPECT (single 
photon emission computed tomography).
2-4
 It has also been used for labelling 




For SPECT imaging a complex is formed between a bifunctional chelator (BFC) and 
the radionuclide which then binds covalently to a specific target, for example, a 




HYNIC is a well-established bifunctional technetium-binding ligand used to 
synthesise technetium-99m-radiolabelled bioconjugates.
8
 HYNIC binds to 
technetium-99m via the hydrazino group to form a Tc-N bond in high yield.
9
 
Conventionally, HYNIC is coupled non-site-specifically with amine groups of lysine 
side chains and N-terminal residues using an activated ester form of Boc-protected 
HYNIC, such as the Boc-HYNIC-n-hydroxysuccinimide ester.  This strategy cannot 
discriminate between different lysine residues and gives non-site-specific labelling.
10
 
Alternatively, an active ester derivative of HYNIC can be used to radiolabel 
antibodies or it can be attached to an amino acid and incorporated into a peptide 
sequence via solid phase peptide synthesis (SPPS) to image site-specific targets.   
26 
 
Since HYNIC serves as a monodentate or bidentate ligand, a coligand is necessary to 
complete the coordination sphere of the technetium core.
11
 (see figure 2.1).  The 
most commonly used co-ligands for HYNIC are tricine and ethylenediamine-N,N-
diacetic acid (EDDA)
12, 13
 (see figure 2.2).  The requirement for co-ligands leads to 
not only a high degree of versatility in design and application of this bifunctional 
chelating system, but also a high degree of uncertainty in the structure of the 
coordination sphere and in how to optimise it to produce radiopharmaceuticals with 
the best convenience and efficiency of labelling, structural homogeneity, in vivo 
stability and targeting properties.
9
 Developments and enhancements to improve its 
efficacy and versatility include designs to allow site specificity, availability of amino 




Figure 2.1: Structures of 
99m
Tc-HYNIC-peptide complexes showing (1) 









Technetium-99m is currently the most widely used radioisotope for SPECT due to 
its easy availability and half-life of 6 hours, resulting in relatively low radioactivity 






2.2 Aims and Objectives 
The 6-hydrazinonicotinyl group, known as HYNIC, is an attractive bifunctional 
coupling agent for preparing 
99m
Tc-labeled peptides and proteins for medical 
imaging. 
The aim of this chapter is to synthesise HYNIC analogues that are capable of 
chelating technetium-99m which can then be attached to an amino acid and 
incorporated into a peptide sequence via solid phase peptide synthesis (SPPS) to 
image site-specific targets.   
Solid Phase Peptide Synthesis (SPPS) is a technique for forming peptides that can be 
readily automated with a robotic synthesiser.
16
 SPPS works by sequentially attaching 
an amino acid to a growing peptide chain supported on a polystyrene resin bead.
17
 
Peptides are specific so they will be taken up selectively in tissues due to the 
presence of a specific receptor for a particular peptide.  Peptides are useful for 
imaging disease states such as cancer and inflammation because they take advantage 
of a distinct cellular target, such as a receptor, being present on the cell.
18
 Receptors 
are often over expressed on tumour cells.  Peptides will bind to their receptors with 
high specificity and affinity.
19
 
Before the active ester derivative of HYNIC can be incorporated into a peptide, the 
hydrazine group must be protected.  This is achieved with a Boc (butoxycarbonyl) 
group, which prevents the highly nucleophilic hydrazine group undergoing unwanted 
side reactions.   
Active esters are improved conjugation reagents which are prepared by the action of 
a dehydrating agent (D) on a ligand containing a free carboxylic acid and a hydroxyl 
on a potential leaving group (L) (see scheme 2.1).  The active ester reacts cleanly 
with deprotonated primary amines to form a very stable amide bond (see scheme 
29 
 






Scheme 2.1: General scheme for the preparation of an active ester. 
 
Scheme 2.2: Reaction of an active ester with a primary amine. 
 
The active ester of Boc-HYNIC is synthesised in this chapter for the subsequent 
conjugation with an amino acid to be incorporated into a peptide sequence via solid 
phase peptide synthesis (SPPS).  Adding HYNIC to the peptide during solid phase 







2.3 Experimental Section 
 
2.3.1 Materials 
Anhydrous sodium sulfate, 6-chloronicotinic acid (99%), N-hydroxysuccinimide 
(98%), water soluble carbodiimide hydrochloride (WSC.HCl) (99%) and hydrazine 
hydrate (80%, hydrazine 51%) were purchased from Acros Organics (Fisher).  2-
chloronicotinic acid (99%) was purchased from Alfa Aesar.  Concentrated 
hydrochloric acid (32%), ammonium chloride, absolute ethanol (analytical reagent 
grade), ethyl acetate (analytical reagent grade), diethyl ether (analytical reagent 
grade) and dimethylformamide were bought from Fisher Scientific.  Triethylamine 
(99%) and di-tert-butyl dicarbonate (99%) were purchased from Sigma Aldrich.  
Dimethyl sulphoxide-d6 (99.9%) was purchased from Goss Scientific Instruments 
Ltd.  All chemicals and solvents were used without further purification.   
 








C nuclear magnetic resonance (NMR) spectra were 
recorded using a JEOL ECS-400 spectrometer at 30°C from solutions in CDCl3.   
IR: The IR spectra were recorded using an IR Affinity-1 Fourier Transform Infrared 
Spectrophotometer Shimadzu.  A small amount of dry solid (about 25-50mg) was 
placed on the sample disc and analysed directly.   
MP: The melting points were recorded using a STUART SMP10 melting point 
model.  The samples were heated at 5 degrees per minute to reach plateau 20 degrees 
31 
 
below approximate melting point and then the sample was ramped at 2 degrees per 
minute to observe the accurate melting point. 
 
2.3.3 Syntheses of HYNIC Analogues 
2.3.3.1 Synthesis of 6-hydrazinonicotinic acid (6-hydrazinopyridine-3-




Scheme 2.3: Reaction scheme for the preparation of 6-hydrazinopyridine-3-
carboxylic acid. 
 
6-Chloronicotinic acid (1.02 g; 6.35 mmol) was added to 80% hydrazine hydrate 
(4.50 ml; 116.28 mmol) and placed in a 100°C oil bath for 4 hours.  The 
homogeneous reaction mixture was cooled to room temperature and concentrated to 
dryness to give a light yellow solid.  The solid was dissolved in water and on 
acidification to pH 5.5 with concentrated hydrochloric acid, a precipitate was 
formed.  The precipitate was isolated by filtration and the solid was washed with 
95% ethanol (100 cm
3
) and ether (100 cm
3
) and dried in a vacuum oven to give 0.72 
g of 6-hydrazinopyridine-3-carboxylic acid as a yellow solid. 
32 
 






 (270 MHz; (CD3)2SO): δ 6.69 (1H, d, J = 8.0 Hz), 7.84 
(1H, dd, J = 2.4, 8.8 Hz), 8.51 (1H, d, J = 2.4 Hz). 
1
H-NMR (399.78 MHz; (CD3)2SO): δ 6.94 (1H, d, J = 8.4 Hz, 5-H), 8.07 (1H, dd, J 
= 2.0, 8.8 Hz, 4-H), 8.63 (1H, d, J = 2.0 Hz, 2-H).  OH proton was observed as a 
broad singlet at 10.24 ppm.  8-H and 9-H were observed as a broad signal between 
2.5 ppm and 4.5 ppm.   
13
C-NMR (100.53 MHz; (CD3)2SO): δ 108.9 (C-5), 118.6 (C-3), 138.9 (C-4), 148.0 
(C-2), 158.1 (C-6), 166.0 (C-7). 
IR: νmax/cm
-1
 3350 (m, N-H stretch, secondary amine) 3223 (m, N-H2 stretch, 





2.3.3.2 Synthesis of 6-BOC-hydrazinopyridine-3-carboxylic acid; ‘BOC-
HYNIC’1 
 
Scheme 2.4: Reaction sequence for the preparation of 6-BOC-hydrazinopyridine-3-
carboxylic acid. 
To a solution of 6-hydrazinopyridine-3-carboxylic acid (0.50 g; 3.26 mmol) and 
triethylamine (0.91 ml; 6.52 mmol) in DMF (8 ml) was added di-tert-buty 
dicarbonate (1.07 g; 4.89 mmol).  The reaction mixture became homogeneous over 1 
hour and stirring was continued for 16 hours at room temperature.  The reaction 
mixture was concentrated to remove as much as DMF as possible under reduced 
pressure to give a yellow solid.  The resulting yellow paste was dissolved in a 
minimum amount of ethyl acetate and shaken in a separating funnel with 8 aliquots 
of saturated ammonium chloride solution (100 cm
3
 each).  The organic layer was 
dried with sodium sulfate and vacuum filtered to give a clear yellow solution.  This 
was concentrated to dryness and dried in a vacuum oven (60°C, 24 hours) to yield a 
yellow solid which was used without further purification.   









 (270 MHz; (CD3)2SO): δ 1.40 (9H, s) 6.52 (1H, d, J = 
8.8 Hz), 7.97 (1H, dd, J = 2.4, 8.8 Hz), 8.58 (1H, d, J = 2.4 Hz). 
1
H-NMR (399.78 MHz; (CD3)2SO): δ 1.34 (9H, s, 12-H) 6.58 (1H, d, J = 8.4 Hz, 5-
H), 7.92 (1H, dd, J = 2.0, 8.0 Hz, 4-H), 8.53 (1H, d, J = 2.0 Hz, 2-H), 8.87 (1H, s, 9-
H) 8.96 (1H, s, 8-H) OH proton was not observed. 
13
C-NMR (100.53 MHz; (CD3)2SO): δ 28.6 (C-12), 79.7 (C-11), 105.0 (C-5), 116.8 
(C-3), 138.9 (C-4), 150.9 (C-2), 156.4 (C-10), 162.8 (C-6), 166.9 (C-7). 
IR: νmax/cm
-1
 3244 (m, N-H stretch, secondary amine) 2978 (m, C-H stretch), 1701, 










Scheme 2.5: Reaction sequence for the preparation of Succinimidyl 6-BOC-
hydrazinopyridine-3-carboxylic acid. 
To a solution of 6-BOC-hydrazinopyridine-3-carboxylic acid (0.10 g; 0.39 mmol) 
and N-hydroxysuccinimide (0.05 g; 0.39 mmol) in DMF (4 ml) was added a solution 
of WSC.HCl (0.08 g; 0.39 mmol) in DMF (2 ml).  The reaction mixture became 
cloudy after 1 hour and stirring was continued for 16 hours at room temperature.  
The reaction mixture was concentrated to remove as much as DMF as possible under 
reduced pressure to give a yellow solid.  The resulting yellow paste was dissolved in 
a minimum amount of ethyl acetate and shaken in a separating funnel with 8 aliquots 
of saturated ammonium chloride solution (100 cm
3
 each).  The organic layer was 
dried with sodium sulfate and vacuum filtered to give a clear yellow solution.  This 
was concentrated to dryness and dried in a vacuum oven (60°C, 24 hours) to yield a 
yellow solid which was used without further purification. The eluate was 
concentrated to dryness to give 0.09 g of a yellow solid, which was recrystallized 
from ethyl acetate/hexanes. 








 (270 MHz; (CD3)2SO): δ 1.41 (9H, s), 2.87 (4H, s), 6.64 
(1H, d, J = 8.8 Hz), 8.08 (1H, dd, J = 2.4, 8.8 Hz), 8.73 (1H, d, J = 2.4 Hz). 
1
H-NMR (399.78 MHz; (CD3)2SO): δ 1.39 (9H, s, 12-H) 2.83 (4H, s, 14H), 6.52 
(1H, d, J = 8.4 Hz), 7.94 (1H, dd, J = 2.2, 8.4 Hz), 8.58 (1H, d, J = 2.2 Hz), 8.94 
(1H, s, 8-H), 9.27 (1H, s, 9-H). 
13
C-NMR (100.53 MHz; (CD3)2SO): δ 24.8 (C-14), 28.6 (C-12), 80.5 (C-11), 105.0 
(C-5), 112.8 (C-3), 139.4 (C-4), 150.9 (C-2), 156.4 (C-6), 162.7 (C-13), 168.9 (C-
10), 170.4 (C-7). 
IR: νmax/cm
-1
 3361 (m, N-H stretch, secondary amine) 2927 (m, C-H stretch), 1734, 
1717 (s, C=O stretch, ester), 1647, 1601 (s, C=O stretch, amide), 1240, 1206, 1153 




2.3.3.4 Synthesis of 2-hydrazinonicotinic acid (2-hydrazinopyridine-3-




Scheme 2.6: Reaction sequence for the preparation of 2- hydrazinopyridine-3-carboxylic 
acid. 
 
2-chloronicotinic acid (1.01 g, 6.44 mmol) was add to 80% hydrazine hydrate (4.60 
ml; 117.98 mmol) and placed in a 100°C oil bath for 4 hours.  The homogeneous 
reaction mixture was cooled to room temperature and concentrated to dryness under 
vacuum to give a yellowish solid.  The solid was dissolved in water; on acidification 
to pH 5.0 with concentrated hydrochloric acid a precipitate was formed.  The 





) and dried in vacuum oven to give 0.50 g of 2-hydrazinopyridine-3-
carboxylic acid as an orange solid. 









 (270 MHz; (CD3)2SO): δ 6.85 (1H, dd, J = 5.1, 7.7 Hz, 
5-H), 8.15 (1H, dd, J = 1.7, 7.7 Hz, 4-H), 8.30 (1H, dd, J = 1.7, 5.1 Hz, 6-H). 
1
H-NMR (399.78 MHz; (CD3)2SO): δ 6.30 (1H, dd, J = 5.2, 7.6 Hz, 5-H), 8.04 (1H, 
dd, J = 2.0, 7.6 Hz, 4-H), 8.18 (1H, dd, J = 2.0, 5.2 Hz, 6-H).  OH proton was 
observed as a broad singlet at 9.31 ppm.  8-H and 9-H were not observed. 
13
C-NMR (100.53 MHz; (CD3)2SO): δ 109.8 (C-3), 112.3 (C-5), 140.9 (C-4), 150.8 
(C-6), 159.4 (C-2), 168.7 (C-7). 
IR: νmax/cm
-1
 3306 (m, N-H stretch, secondary amine) 3202 (m, N-H2 stretch, 











Scheme 2.7: Reaction sequence for the preparation of 2-BOC-hydrazinopyridine-3-
carboxylic acid. 
 
To a solution of 2-hydrazinopyridine-3-carboxylic acid (0.10 g; 0.65 mmol) and 
triethylamine (0.13 ml; 1.30 mmol) in DMF (2 ml) was added di-tert-buty 
dicarbonate (0.21 g; 0.98 mmol).  The reaction mixture became homogeneous over 1 
hour and stirring was continued for 16 hours at room temperature.  The reaction 
mixture was concentrated to remove as much as DMF as possible under reduced 
pressure to give a yellow solid.  The resulting yellow paste was dissolved in a 
minimum amount of ethyl acetate and shaken in a separating funnel with 8 aliquots 
of saturated ammonium chloride solution (100 cm
3
 each).  The organic layer was 
dried with sodium sulfate and vacuum filtered to give a clear yellow solution.  This 
was concentrated to dryness and dried in a vacuum oven (60°C, 24 hours) to yield a 
yellow solid which was used without further purification.   






H-NMR (399.78 MHz; (CD3)2SO): δ 1.42 (9H, s, 12-H) 6.62 (1H, dd, J = 5.0, 7.4 
Hz, 5-H), 8.04 (1H, dd, J = 2.0, 7.4 Hz, 4-H), 8.54 (1H, dd, J = 2.0, 5.0 Hz, 6-H), 
8.86 (1H, s, 9-H) 8.92 (1H, s, 8-H) OH proton was not observed. 
13
C-NMR (100.53 MHz; (CD3)2SO): δ 28.9 (C-12), 80.2 (C-11), 108.0 (C-3), 115.8 
(C-5), 139.6 (C-4), 152.9 (C-6), 156.7 (C-10), 160.8 (C-2), 168.9 (C-7). 
IR: νmax/cm
-1
 3301 (m, N-H stretch, secondary amine) 3117 (m, N-H stretch, 
primary amine) 2996 (m, O-H stretch, carboxylic acid), 1681 (s, C=O stretch, 
carboxylic acid). 









To a solution of 2-BOC-hydrazinopyridine-3-carboxylic acid (0.1 g; 0.39 mmol) and 
N-hydroxysuccinimide (0.05 g; 0.39 mmol) in DMF (4 ml) was added a solution of 
WSC.HCl (water soluble carbodiimide hydrochloride) (0.08 g; 0.39 mmol) in DMF 
(2 ml).  The reaction mixture became cloudy after 1 hour and stirring was continued 
for 16 hours at room temperature.  The reaction mixture was filtered and the filtrate 
was concentrated to dryness to give a brown residue.  The residue was dissolved in a 
minimum amount of ethyl acetate and passed through silica gel 60 (230-400mesh) 
using ethyl acetate as an eluant.  The eluate was concentrated to dryness to give 0.09 
g of a yellow solid, which was recrystallized from ethyl acetate/hexanes.  
1
H NMR 
indicated that the reaction was unsuccessful and due to time constraints, it could not 




2.4 Results and Discussion 
Both 2-hydrazinopyridine-3-carboxylic acid (2-HYNIC), 6-hydrazinopyridine-3-
carboxylic acid (6-HYNIC) and their BOC-protected forms were synthesised 





 The activated ester form of 6-BOC-HYNIC was also successfully 
synthesised however the activated ester form of 2-BOC-HYNIC was unsuccessful.   
2.4.1 6-HYNIC 
The commercially available and cheap 6-chloronicotinic acid was chosen as the 
starting material for the synthesis of 6-HYNIC.  6-hydrazinopyridine-3-carboxylic 
acid was formed via an aromatic substitution reaction using 80% hydrazine hydrate 




C-NMR were used to analyse the identity and purity of the compound.  The 
melting point of 285-288°C (literature 292-293°C) indicates the purity of the 
compound.  The NMR and IR spectra elucidate the structure of the compound.   
The synthesis of 6-HYNIC required several attempts and modifications to the 
literature preparation in order to be successful.  The literature calls for 8.0g of 6-
chloronicotinic acid to be added to 35ml of hydrazine hydrate and placed in a 100°C 
oil bath for 4 hours.  It was decided that 6-HYNIC would be prepared initially 
according to the literature but on a smaller scale; 0.5417g of 6-chloronicotinic acid 
was added to 2.427ml of hydrazine hydrate.  The literature indicated that after 
cooling to room temperature and concentrating to dryness, a white solid would be 
formed, however a yellow solid was obtained.  The method also stated that the solid 
should be dissolved in water and acidified to pH 5.5 to give a precipitate, however 
none formed.  At this stage it was unclear why a precipitate did not form at pH 5.5 so 
the acidification with HCl was continued until a yellow precipitate formed at pH 2.3.  
The precipitate was filtered and washed with 95% ethanol and ether and dried to give 
1.4304g of product.  
1
H-NMR did not confirm the product to be 6-HYNIC - the 
NMR spectrum shows one broad peak in the aromatic region. The only difference 
43 
 
between the starting material and the desired product is a substitution of the chloride 
for an amine group, therefore the signals observed in the NMR for the pyridine ring 
would also theoretically be present in the product. The solid was then recrystallised 
in water in an effort to remove any impurities to give 0.3203g of solid. Again the 
NMR was inconclusive.  
At this stage it was unclear why the reaction was unsuccessful. Due to the small 
scale of the reaction, the yields were minimal and it could be that given this low 
yield, the precipitate was not obtained. It was decided that the reaction would be 
scaled up in order to obtain a significant quantity to isolate. The method was 
repeated as before, however this time 1.0201g of 6-chloronicotinic acid was added to 
4.530ml of hydrazine hydrate and prepared according to previous method. During 
the acidification stage a viscous liquid formed rather than a precipitate. 0.2113g of 
solid precipitate was then isolated from the material. Again 
1
H-NMR did not confirm 
the product to be 6-HYNIC (no corresponding peaks to literature data).  Several 
further attempts and minor changes to the literature preparation were made to 
successfully synthesise 6-HYNIC. 
In the successful preparation of 6-HYNIC, 1.0201g of 6-chloronicotinic acid and  
4.530ml of hydrazine hydrate were added, under an inert atmosphere, and the 
reaction mixture was acidified to pH 3.0. 0.72g (74% yield) of a yellow solid formed 
and 
1
H NMR spectrum confirms the product to be 6-HYNIC. 
In the 
1
H-NMR spectrum of 6-HYNIC (see figure 2.3), six proton peaks are 
detectable, as is expected.  The first peak in the aromatic region of the NMR 
spectrum is the aromatic proton 5-H, which is detected at 6.94  ppm, and is a doublet 
with a coupling constant of 8.4Hz.  Further downfield, the 4-H proton in the pyridine 
ring, is determined by a peak at 8.07 ppm which is a double doublet with coupling 
constants of 2.0Hz and 8.4Hz.  The coupling between the neighbouring protons 4-H 
and 5-H is shown by the same coupling constant.  4-H also couples with another 
proton shown by the coupling constant 2.0Hz.  The 4-H proton has a higher chemical 
shift than the 5-H proton, this is due to it’s proximity to the carboxylic acid group, 
which has an electron withdrawing effect.  Further downfield, there is a doublet peak 
at 8.63 ppm which determines the aromatic proton 2-H.  This 2-H proton has a 
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coupling constant of 2.0Hz and shows long range coupling between the 2-H proton 
and the 4-H proton.  The 2-H proton is further downfield, i.e.  has a higher chemical 
shift, than the 4-H proton due to it’s proximity to the nitrogen in the ring, which also 
has an electron withdrawing effect.  The 4-H and 5-H protons are shifted further 
downfield due to the resonance effect.  Resonance structures will leave a lack of 
electron density in the ortho and para positions with respect to the carboxylic acid 
group.  The carboxylic acid proton was observed in this spectrum as a broad singlet 
at 10.24 ppm, which is where it is expected (10-13 ppm).  The 8-H and 9-H protons 
on the NH2 group were observed as a very broad signal ranging from 2.5 ppm to 4.5 
ppm.  O-H and N-H protons are not always observed in NMR spectra as their 
presence is concentration dependant and their position can alter in the spectrum.  
Unlike carbon bonded protons, N-H and O-H protons do not tend to couple with 









C-NMR spectra for 6-HYNIC shows six carbon peaks, as expected.  Using the 
same numbering system as for the 
1
H-NMR  interpretation, C-5 is shown at 108.9 
ppm, C-4 is shown at 138.9 ppm, and C-2 is shown at 148.0 ppm.  Again, C-2 is 
furthest downfield, followed by C-4 and C-5.  C-3 and C-6 are not bonded to a 
proton, and are shown at 118.6 ppm and 158.1 ppm respectively.  The C-3 carbon is 
in para position to the hydrazine group which is electron donating and therefore has 
a lower chemical shift due to the added electron density.  This added electron density 
shields the carbon from the magnetic field.  The opposite is true for the carbon at C-
6.  The C-6 carbon at 158.1 ppm is in para position to the carboxylic acid group, 
which has an electron withdrawing effect.  The lack of electron density means that 
C-6 is not shielded from the magnetic field and consequently has a higher chemical 
shift.  The peak at 166.0 ppm determines the C-7 carbon of the carboxylic acid 
group.  This carbon has a high chemical shift due to the electronegative oxygens on 
the carboxylic acid group.   
The IR spectrum for 6-HYNIC shows each of the functional groups that are 
expected; 3350 (m, N-H stretch, secondary amine) 3223 (m, N-H stretch, primary 
amine), 2691 (m, O-H stretch, carboxylic acid), 1663 (s, C=O stretch, carboxylic 
acid).  These functional groups are all present in the structure of HYNIC and help to 
identify the compound as 6-HYNIC.  Not every peak present in the spectra is noted 
here, just enough peaks to indicate the correct functional groups in the spectra for all 
compounds.   




C-NMR and IR spectroscopy confirm the successful 
synthesis of 6-HYNIC. 
 
2.4.2 6-BOC-HYNIC 
6-HYNIC was further reacted with di-tert-butyldicarbonate in triethylamine (TEA) 
to give 6-BOC-hydrazinopyridine-3- carboxylic acid in 98% yield.  Melting point, 
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C-NMR were used to analyse the identity and purity of 
the compound.  The melting point of 142-145°C indicates the purity of the 
compound.  The NMR and IR spectra confirm the structure of the compound.   
The literature preparation calls for  2.13g of di-tert-buty dicarbonate to be added to a 
solution of 1.40g of 6-HYNIC and 1.2ml of triethylamine in 10ml DMF. Due to a 
limited supply of the starting material (the previously sunthesised 6-HYNIC), the 
reaction was scaled down and instead, 0.1425g of di-tert-buty dicarbonate was added 
to a solution of 0.10g of 6-HYNIC and 0.109ml of triethylamine in 1ml of DMF. 
This reaction mixture was stirred for 17 hours at room temperature. According to the 
literature the reaction mixture should then be concentrated to dryness under reduced 
pressure however the solid was not separated as it was not possible to successfully 
remove the solvent, even with gentle, and then more vigorous heating.  
The synthesis was attempted again and, as before, 0.1425g of di-tert-buty 
dicarbonate was added to a solution of 0.10g of 6-HYNIC and 0.109ml of 
triethylamine in 1ml of DMF. This reaction mixture was stirred for 19 hours at room 
temperature. The reaction mixture was concentrated to dryness under reduced 
pressure to give a yellowish solid (unlike the literature which states that a brown 
solid is formed). According to the method, the solid should then be dissolved in ethyl 
acetate and passed through silica gel. Unfortunately, at this stage the solid obtained 
was found to be isoluble in ethyl acetate so a more polar solvent, methanol, was 
used. 
1
H NMR indicated the presence of starting material and solvent rather than the 
desired product.  
At this point it was uncertain as to why the reactions were unsuccessful; several 
further attempts and changes to the literature preparation were made to successfully 
synthesise 6-Boc-HYNIC. 
1
H NMR spectra of subsequent syntheses either indicated 
the presence of starting material, suggesting the reaction did not go to completion, or 
were inconclusive.  
In the successful preparation of 6-Boc-HYNIC, 1.07g (4.89 mmol) of di-tert-buty 
dicarbonate was added to a solution of 6-hydrazinopyridine-3-carboxylic acid (0.50 
g; 3.26 mmol) and triethylamine (0.91 ml; 6.52 mmol) in DMF (8 ml) under an inert 
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atmosphere. The reaction mixture became homogeneous over 1 hour and stirring was 
continued for 16 hours at room temperature.  The reaction mixture was concentrated 
to remove as much DMF as possible under reduced pressure to give a yellow solid.  
The resulting yellow paste was dissolved in a minimum amount of ethyl acetate and 
shaken in a separating funnel with 8 aliquots of saturated ammonium chloride 
solution (100 cm
3
 each).  The organic layer was dried with sodium sulfate and 
vacuum filtered to give a clear yellow solution.  This was concentrated to dryness 
and dried in a vacuum oven (60°C, 24 hours) to yield a yellow solid which was used 
without further purification.   
In the 
1
H -NMR spectrum of 6-BOC-HYNIC, a singlet peak at 1.34 ppm determines 
the BOC group.  This peak shows as a singlet due to the fact that all the protons in 
the CH3 groups share the same environment and are therefore equivalent.  This peak 
has a lower chemical shift than the other protons in the spectrum due to the electron 
donating effect of the three methyl groups on the BOC group.  The aromatic protons; 
5-H, 4-H and 2-H are detected at similar values to the 
1
H -NMR spectrum of 6-
HYNIC; 6.58 ppm, 7.92 ppm and 8.53 ppm respectively.  The 8-H proton is 
observed as a singlet at 8.96 ppm, and the 9-H proton is observed as a singlet at 8.87 
ppm.  The 7-H proton is not observed in this spectrum.  Neither the N-H protons nor 
the O-H protons are present in the literature NMR spectrum, but all other protons for 
6-BOC-Hynic are in good agreement with the literature.   
The 
13
C-NMR spectra for 6-BOC-HYNIC shows nine carbon peaks, as expected.  
The BOC group carbon, C-12 is observed at 28.6 ppm, and the other BOC group 
carbon, C-11 is observed at 79.7 ppm.  The C-11 carbon is shown at a higher 
chemical shift than the other BOC group carbons as it is next to an oxygen atom and 
has no hydrogens attached to it, therefore has less electron density.  The C-10 carbon 
is observed at 156.4 ppm due to the proximity of the neighbouring oxygens which 
take the electron density away from the carbon, causing it to have a higher chemical 
shift.  The other carbons are in the 
13
C-NMR spectra are in good agreement with the 
previous carbons in the 
13
C-NMR spectra for 6-HYNIC.   
48 
 
The IR spectrum for 6-BOC-HYNIC shows each of the functional groups that are 
expected; 3244 (m, N-H stretch, secondary amine) 2978 (m, C-H stretch), 1701, 
1683 (s, C=O stretch, carboxylic acid), 1240, 1205, 1153 (s, C-O stretch, ester).  
These functional groups are all present in the structure of 6-BOC-HYNIC and help 
to identify the compound as 6-BOC-HYNIC. 
 
2.4.3 NHS-HYNIC-BOC 
6-BOC-HYNIC was further reacted with N-hydroxysuccinimide in the presence of 
WSC.HCl (water soluble carbodiimide hydrochloride) to give succinimidyl 6-BOC-
hydrazinopyridine-3-carboxylic acid in 62% yield compared to 60% in the literature.  




C-NMR were used to analyse the 
identity and purity of the compound.  The melting point of 166-167°C (literature 
169.5-172°C) indicates the purity of the compound.  The NMR and IR spectra 
elucidate the structure of the compound.   
The protons in the 
1
H-NMR spectrum of NHS-6-HYNIC-BOC are in good 
agreement with the protons from the 6-BOC-HYNIC spectrum.  The succinimidyl 
CH2 (14-H) protons are determined by a singlet peak at 2.83 ppm.  The peak for the 
14-H protons is shown as a singlet because the four succinimidyl protons are 
equivalent.  The two N-H protons, 8-H and 9-H, have shifted to a slightly higher 
chemical shift when compared with the 
1
H-NMR spectrum of 6-BOC-HYNIC.  All 
other proton peaks are in good agreement with the previous 
1
H -NMR spectrum.   
The 
13
C-NMR spectra for NHS-6-HYNIC-BOC shows eleven carbon peaks as 
expected.  The C-14 peak for the two succinimidyl carbons is shown at 24.8 ppm.  
The two carbonyl carbons, C-13, are observed at 162.7 ppm.  C-12 is observed at 
28.6 ppm, C-11 is observed at 80.5 ppm, C-5 is observed at 105.0 ppm, C-3 is 
observed at 112.8 ppm, C-4 is observed at 139.4 ppm, C-2 is observed at 150.9 ppm, 
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C-6 is observed at 156.4 ppm, C-13 is observed at 162.7 ppm, C-10 is observed at 
168.9 ppm and finally, C-7 is observed at 170.4 ppm. 
The IR spectrum for NHS-6-HYNIC-BOC shows each of the functional groups that 
are expected; 3361 cm
-1
 (m, N-H stretch, secondary amine) 2927 cm
-1
















 (s, C-O stretch, ester) .  These 
functional groups are all present in the structure of NHS-6-HYNIC-BOC and help to 
identify the compound as NHS-6-HYNIC-BOC. 
 
2.4.4 2-HYNIC 
For the synthesis of 2-HYNIC, the commercially available and cheap 2-
chloronicotinic acid was chosen as the starting material.  2-hydrazinopyridine-3-
carboxylic acid was formed via an aromatic substitution reaction using 80% 





NMR were used to analyse the identity and purity of the compound.  The melting 
point of 194-196°C indicates the purity of the compound.  The NMR and IR spectra 
elucidate the structure of the compound.   
The synthesis of 2-HYNIC proved to be less complex than the synthesis of 6-
HYNIC although still non-trivial. Several modifications were made to the literature 
preparation, again, as with the other HYNIC analogues and derivatives, the reaction 
was scaled down initially which proved to be problematic in gaining a useful amount 
of product. 0.50 g of 2-chloronicotinic acid was added to 2.27 ml of hydrazine 
hydrate. 
1
H NMR showed that reactions on this scale proved to be unsuccessful or 
inconclusive. Scaling up the procedure gave more promising results and in the 
successful synthesis of 2-HYNIC 1.01g of 2-chloronicotinic acid was add to 4.60 ml 
of 80% hydrazine hydrate. The reaction was undertaken according to a modified 
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literature preparation and 0.50 g of 2-hydrazinopyridine-3-carboxylic acid was given 
as an orange solid. 
1




H -NMR spectrum of 2-HYNIC (see figure 2.4),  all of the six expected 
proton signals are detected.  The first peak in the aromatic region of the NMR 
spectrum is the aromatic proton 5-H, which is detected at  6.30 ppm, and is a double 
doublet with coupling constants of 5.2 Hz and 7.6 Hz.  Further downfield, the 4-H 
proton in the pyridine ring, is determined by a peak at 8.04  ppm which is a double 
doublet with coupling constants of 2.0 Hz and 7.6 Hz.  The coupling between the 
neighbouring protons 4-H and 5-H is shown by the same coupling constant (7.6 Hz).  
4-H also couples with another proton as shown by the coupling constant 2.0Hz.  The 
4-H proton has a higher chemical shift than the 5-H proton, this is due to it’s 
proximity to the carboxylic acid group, which has an electron withdrawing effect.  
Further downfield, there is a double doublet peak at 8.18 ppm which determines the 
aromatic proton 6-H.  This 6-H proton has coupling constants of 2.0 Hz and 5.2 Hz 
and shows coupling with the neighbouring 5-H proton (5.2 Hz) as well as long range 
coupling between the 6-H proton and the 4-H proton (2.0 Hz).  The 6-H proton is 
further downfield, i.e.  has a higher chemical shift, than the 4-H proton due to it’s 
proximity to the nitrogen in the ring, which also has an electron withdrawing effect.  
The 4-H and 6-H protons are shifted further downfield due to the resonance effect.  
Resonance structures will leave a lack of electron density in the ortho and para 
positions with respect to the carboxylic acid group.  The carboxylic acid proton, -
OH, was observed in this spectrum as a broad singlet at 9.31 ppm, which is about 
where it is expected.  The 8-H and 9-H protons on the NH2 group were observed 
between 4 and 5 ppm.  O-H and N-H protons are not always observed in NMR 
spectra as their presence is concentration dependant and their position can alter in the 
spectrum.  Unlike carbon bonded protons, N-H and O-H protons do not tend to 










C-NMR spectra for 2-HYNIC shows six carbon peaks, as expected.  C-5 is 
shown at 112.3  ppm, C-4 is shown at 140.9  ppm, and C-6 is shown at 150.8  ppm.  
C-6 is furthest downfield, followed by C-4 and C-5.  C-3 and C-2 are not bonded to a 
proton, and are shown at 109.8 ppm and 159.4 ppm respectively.  The C-3 carbon is 
in ortho position to the hydrazine group which is electron donating and therefore has 
a lower chemical shift due to the added elctron density.  This added electron density 
shields the carbon from the magnetic field.  The C-2 carbon is in ortho position to 
the carboxylic acid group, which has an electron withdrawing effect.  The lack of 
electron density means that C-2 is not shielded from the magnetic field and 
consequently has a higher chemical shift.  The peak at 168.7  ppm determines the C-
7 carbon of the carboxylic acid group.  This carbon has a high chemical shift due to 
the electronegative oxygens on the carboxylic acid group.   
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The IR spectrum for 2-HYNIC shows each of the functional groups that are 
expected; 3306cm
-1
 (m, N-H stretch, secondary amine) 3202 cm
-1
 (m, N-H stretch, 
primary amine), 2950 cm
-1
 (m, O-H stretch, carboxylic acid), 1655 cm
-1
 (s, C=O 
stretch, carboxylic acid).  These functional groups are all present in the structure of 
HYNIC and help to identify the compound as 2-HYNIC.  Not every peak present in 
the spectra is noted here, just enough peaks to confirm the correct functional groups 
in the spectra for all compounds.   




C-NMR and IR spectroscopy confirm the successful 
synthesis of 2-HYNIC.   
 
2.4.5 2-BOC-HYNIC 
2-HYNIC was further reacted with di-tert-butyldicarbonate in triethylamine (TEA) 
to give 2-BOC-hydrazinopyridine-3- carboxylic acid in 86% yield.  The reaction 
scheme for 2-HYNIC was adapted from the 6-HYNIC reaction scheme.  Melting 




C-NMR were used to analyse the identity and 
purity of the compound.  The melting point of 165°C indicates the purity of the 
compound.  The NMR and IR spectra elucidate the structure of the compound.   
As with 6-Boc-HYNIC, several attempts were necessary to give the optimum 
reaction conditions for the synthesis of 2-Boc-HYNIC. Temperature, time, solvent 




H -NMR spectrum of 2-Boc-HYNIC, a singlet peak at 1.42 ppm determines 
the Boc group.  This peak shows as a singlet due to the fact that all the protons in the 
CH3 groups share the same environment and are therefore equivalent.  This peak has 
a lower chemical shift than the other protons in the specrum due to the electron 
donating effect of the three methyl groups on the Boc group.  The aromatic protons; 
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5-H, 4-H and 6-H are detected at similar values to the 
1
H-NMR spectrum of 2-
HYNIC.  The 8-H proton is observed as a singlet at 8.86 ppm, and the 9-H proton is 
observed as a singlet at 8.92 ppm.  The 7-H proton is not observed in this spectrum.  
Neither the N-H protons nor the O-H protons are present in the literature NMR 
spectrum, but all other protons for 2-Boc-Hynic are in good agreement with the 
literature.   
The 
13
C-NMR spectra for 2-Boc-HYNIC shows nine carbon peaks, as expected.  The 
BOC group carbon, C-12 is observed at 28.9  ppm, and the other BOC group carbon, 
C-11 is observed at 80.2 ppm.  The C-11 carbon is shown at a higher chemical shift 
than the other BOC group carbons as it is next to an oxygen atom and has no 
hydrogens attached to it, therefore has less electron density.  The C-10 carbon is 
observed at 156.7 ppm due to the proximity of the neighbouring oxygens which take 
the electron density away from the carbon, causing it to have a higher chemical shift.  
The other carbons are in the 
13
C-NMR spectra are in good agreement with the 
previous carbons in the 
13
C-NMR spectra for 2-HYNIC.   
The IR spectrum for 2-Boc-HYNIC shows each of the functional groups that are 
expected; 3301 (m, N-H stretch, secondary amine) 3117 (m, N-H stretch, primary 
amine) 2996 (m, O-H stretch, carboxylic acid), 1681 (s, C=O stretch, carboxylic 
acid).  These functional groups are all present in the structure of 2-Boc-HYNIC and 
help to identify the compound as 2-Boc-HYNIC. 
 
2.4.6 Further Modifications to Literature Prep 
Several attempts were necessary to successfully add the Boc protection group to the 
HYNIC analogues.  Research of the literature in this area indicated that the ratio of 
reagents; chloronicotinic acid (1 equivalent), triethylamine (TEA) (1.2 equivalent) 
Boc (1 equivalent), is not optimum.  Changing the ratio of moles of the starting 
materials improved the synthesis and yield of the obtained product.  TEA is used in 
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this reaction to remove any salt formed; in this case hydrogen chloride is formed.  
The NMR spectra of several failed attempts at the synthesis of Boc-HYNIC 
indicated that there was still a significant amount of hydrogen chloride present at the 
end of the reaction.  Increasing the ratio of TEA to chloronicotinic acid improved the 
synthesis of both 2-Boc-HYNIC and 6-Boc-HYNIC.  The molar ratio of 
chloronicotinic acid to TEA recommended in the literature was 1:1.2.  The molar 
ratio was changed to 1:2.  In the case of 6-Boc-HYNIC, the yield was improved from 
78% to 98%. The molar ratio of chloronicotinic acid to di-tert-butyldicarbonate was 
recommended to be 1:1 as per the literature.  However after several failed attempts at 
this synthesis, the molar ratio was changed to 1:1.5 with the Boc in excess.  This 
allowed the synthesis to proceed and the overall yield was improved.   
In the synthesis of succinimidyl 6-Boc-hydrazinopyridine-3-carboxylic acid and 
succinimidyl 2-Boc-hydrazinopyridine-3-carboxylic acid, WSC.HCl (water soluble 
carbodiimide hydrochloride) was used as a coupling agent instead of 
dicyclohexylcarbodiimide (DCC) to prepare the active esters.  WSC.HCl is a 
versatile coupling agent which can be used under aqueous conditions, and therefore 
offers a distinct advantage over DCC as it can easily be removed after reaction by 










2.5 Conclusions and Future Work 
The 6-hydrazinonicotinyl group, known as HYNIC, is an attractive bifunctional 
chelating agent for preparing 
99m
Tc-labelled peptides and proteins for medical 
imaging.  Two different HYNIC analogues (2-HYNIC and 6-HYNIC) and their 
BOC-protected forms were synthesised in high yields.  The syntheses of these 
compounds are non-trivial and required multiple attempts and several changes to the 





NMR spectra for these reactions have shown to be either unsuccessful or 
inconclusive, demonstrating the limitations of the approach for synthesising HYNIC 
and its analogues.   
6-HYNIC has been synthesised according to a modified prep in 74% yield.  6-Boc-
HYNIC has been synthesised according to a modified prep in 98% yield.  NHS-
HYNIC-BOC has been synthesised according to a modified prep in 98% yield.  2-
HYNIC has been synthesised according to a modified prep in 51% yield.  2-Boc-
HYNIC has been synthesised according to a modified prep in 86% yield.   
Due to time constraints of the project, the HYNIC analogues were not radiolabelled 
with technetium-99m, nor were the use of novel co-ligands to saturate the 
coordination sphere of technetium tested.   
There are a number of variables to be explored in this field such as BFCs, 
radioisotopes, ligands and choice of targeting molecule.  To start with, while 6-
HYNIC has shown to be an important BFC in binding radiometals to target 
molecules, it is not without its limitations.  One of the main areas of research 
concerns the uncertainty of the structure of the coordination sphere of the technetium 
core, specifically in how to optimise it to produce radiopharmaceuticals with the best 
convenience and efficiency of labelling, structural homogeneity, in vivo stability and 
targeting properties.  6-HYNIC cannot saturate the coordination sphere of 
technetium which means that the use of co-ligands is required.  Co-ligands, such as 





 Tricine, for example, allows for quick labelling and high specific activity 
under mild conditions, however, it produces a mixture of isomeric complexes.
6, 14
 
EDDA allows for improved stability and homogeneity but requires heating and does 
not easily coordinate directly with technetium-99m.
14, 22
 Future work in this field 
could include the design of alternative co-ligands to satisfy the technetium-99m 
coordination sphere which allow for efficient labelling, high specific activity and 
stability, and reduced isomeric complexes, under mild conditions to allow for direct 
labelling with larger peptides and proteins. 
Additionally, further HYNIC analogues such as 2-HYNIC and 4-HYNIC have yet to 
be fully explored.  The use of 2-HYNIC as an efficient BFC for technetium-99m 
complexes may show promise.  Meszaros et al.  showed that the coordination 
chemistry of 2-HYNIC with technetium-99m is similar to the coordination chemistry 
of 6-HYNIC with technetium-99m.
21
 While 6-HYNIC is widely used as a BFC for 
radiolabelling biomolecules including peptides and proteins, 2-HYNIC is not as 
widely used and has not yet been incorporated into peptides.  Further research could 
include utilising the success of 6-HYNIC as a BFC for radiolabelling with 
technetium-99m, with a view to replicating that success with 2-HYNIC and 
determining whether 2-HYNIC gives analogous results to 6-HYNIC.  2-HYNIC may 
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Chapter 3 - Synthesis of POEGMA-co-PAMA for Binding 
with HYNIC 
3.1 Introduction to Polymers 
A polymer is defined as a large molecule constructed of many smaller repeating 
structural units, called monomers, that are covalently bonded together.
1, 2
 The term 
polymer derives from the Greek 'poly' meaning 'many' and 'mer' meaning 'units'.  
Monomers possess two or more bonding sites, through which they can be linked to 
other monomers to form the chain.  The chemical bonds within the chain are very 
strong and directional along the chains; linear chains are most easily produced, 
however, chains can be linked together, by changing the chemistry involved, i.e.  the 
use of polyfunctional monomers, to produce branched and network structures.
3
 
Formally, polymers that contain only one species of monomer are called 
homopolymers (see figure 3.2 - A).
4
 Although polymers which contain a single type 
of repeat unit, containing one or more monomer species, are also termed 
homopolymers.
5
 An example of a homopolymer, is poly(methyl methacrylate), 
(PMMA), which is named for its monomeric composition; PMMA is made up of 
repeating units of the methyl methacrylate monomer (see figure 3.1).  The number 
of repeating units, in the polymer chain is termed the degree of polymerisation, DP.
2
 
The higher the DP the higher the molecular weight.
6
 Here, n represents the number 
of repeating units: 
 
Figure 3.1: Methyl methacrylate subunit in a poly(methyl methacrylate) polymer. 
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Polymers can be separated into two classes: natural polymers and synthetic 
polymers.  Examples of synthetic polymers include nylon and poly(vinyl chloride) 
(PVC).  Examples of naturally occurring polymers include proteins, 





Chains that are composed of two different types of monomer are called copolymers.  
There are four main types of copolymers; statistical copolymers, alternating 
copolymers, block copolymers and graft copolymers.
8-10
 
Alternating copolymers (see figure 3.2 - C) are characterised by the regular 
alternating placement of the two monomers (in equimolar composition) along the 
chain.
11
 Special reaction conditions are necessary for producing alternating 
copolymers making this type of copolymer relatively rare.  They are virtually 
impossible to produce by a free radical route and require pairs of monomers with 
highly specific copolymerisation reactivity ratios.  The synthesis of alternating 
copolymers gives homogeneous systems that display properties representing a 
weighted average of the two repeat units.
12
 
Block copolymers (see figure 3.2 - B) are comprised of substantial sequences or 
blocks of each monomer.  The chemically distinct polymer chains are linked together 
at one or more intersections through covalent or non-covalent bonds.  Block 
copolymers tend to show characteristic properties of the constituent homopolymers.  
They are usually prepared from living chain polymers or from step-growth systems 
which allow the control of block integrity and sequential architecture that is so 
important for achieving the desirable properties.
5, 12, 13
 
Graft copolymers (see figure 3.2 - E) are polymers in which blocks of one monomer 
are grafted onto a backbone of the other as branches.
1, 8
 They can be described as 
chemically linked homopolymer pairs, and as such are similar to block copolymers; 
like block copolymers, graft copolymers tend to show characteristic properties of the 
constituent homopolymers.  Graft copolymers are prepared by free-radical, anionic 
or cationic addition polymerisation.  These copolymers provide the basis for many 
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commercially important polymers such as impact polystyrene and acrylonitrile 
butadiene styrene (ABS).5, 12, 14 
Statistical copolymers (see figure 3.2 - D) are copolymers in which the distribution 
of the two monomers is random but influenced by the individual monomer 
reactivities.  The two monomers are simultaneously copolymerised resulting in 
modifications to the mechanical and physical properties of the polymer.  Choosing 
monomers with reactivity ratios close to 1 produces statistical copolymers.  







Figure 3.2: Representation of the different types of polymer; (A) a homopolymer, 
(B) block copolymer, (C) alternating copolymer, (D) statistical copolymer, (E) graft 
copolymer. 
Copolymers are produced to give improved properties as they often exhibit a 
combination of the best properties of their components.  An example is the 







3.1.1.1 Block Copolymers 
Block copolymers (see figure 3.2) contain at least two types of monomer that have 
been polymerised in succession so that each monomer sequence forms a different 
block.  The blocks are connected by a covalent bond that is formed during the 




Figure 3.3: General notation for a block copolymer where A and B represent 
different monomer blocks, b is an abbreviation of block, and x and y represent the 
degree of polymerisation (DP).   
 
Mixtures containing two or more homopolymers which are composed of chemically 
different monomers tend to undergo phase-separation.
17, 18
 This is where the 
components separate resulting in poor overall properties of the mixture.  It is 
therefore desirable to have a chemical bond between the two homopolymers to avoid 
separation.  Block copolymers offer an advantage over other copolymers which is 
the ability to have polymers which are chemically different, and therefore 
incompatible, covalently bonded in the same macromolecule without undergoing 
macrophase separation.  This means that the chemical and physical properties, such 





3.2 Polymerisation Techniques 
Polymerisation is the process by which monomer molecules are converted into a 
polymer.  The two most important types are step-growth polymerisation and chain-
growth polymerisation. 
 
3.2.1 Step-growth Polymerisation 
Step-growth polymerisation usually, although not always, involves typical 
condensation reactions where a small molecule, e.g.  H2O or HCl is expelled as the 
link is built. 
In step-growth polymerisation, a linear chain of monomer residues is obtained by the 
stepwise intermolecular condensation or addition of the reactive groups in 
bifunctional monomers.  Any two molecular species in the mixture can react and the 
monomer is almost all incorporated into a chain molecule in the early stages of the 
reaction.  In step-growth polymerisation, initiation, propagation and termination 
reactions are essentially identical in rate and mechanism.  The chain length increases 
steadily as the reaction proceeds and long reaction times and high conversions are 
necessary for the production of a polymer with a large number-average chain length.  
The reaction rates for this type of polymerisation are slow at ambient temperatures 
but increase with a rise in temperature, although this has little effect on the chain 




3.2.2 Chain-growth Polymerisation 
Chain-growth polymerisations involve the addition of unsaturated monomers where 
the special reactivity of π-bonds in the carbon to carbon double bond makes them 
susceptible to rearrangement if activated by free-radical or ionic initiators.  The 
polymerisation proceeds in 3 steps: (1) initiation, when the active centre is created; 
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(2) propagation, involving growth of the chain by a kinetic chain mechanism; and 
(3) termination, where the kinetic chain is terminated by the neutralisation of the 
active centre.  In chain-growth polymerisations,  high degrees of polymerisation are 
attained at low monomer conversions and the average chain length shows little 
variation throughout the course of the polymerisation.  The monomer concentration 
decreases steadily throughout the reaction.  In this type of polymerisation, only the 
active centre can react with the monomer and add units onto the chain one after the 
other.  Long reaction times increase the polymer yield, but not the molar mass of the 
polymer and an increase in temperature increases the rate of the reaction but 




3.2.3 Free Radical Polymerisation 
A free radical is a species containing an unpaired electron.  The radical is capable of 
reacting with an olefinic monomer to generate a chain carrier that can propagate a 
macromolecular chain under the appropriate conditions.
20
 
Free radical polymerisations proceed in four steps: (1) initiation, when the active 
centre is created; (2) propagation, where monomer molecules are added one by one 
to the active chain end.  The reactive site is regenerated after each addition of 
monomer; (3) transfer, this occurs when an active site is transferred to an 
independent molecule such as a monomer, initiator, polymer, or solvent.  This 
process results in both a terminated molecule and a new active site that is capable of 
undergoing propagation; (4) termination, where the eradication of active sites leads 
to “terminated” or inert, macromolecules.  Termination occurs via coupling reactions 




Free radical polymerisation techniques can be conducted at a wide range of 
temperatures and in the presence of water and as such they provide a viable synthetic 
method for the production of large molecular weight polymers on an industrial scale.  
However, free radical polymerisation techniques offer no control over the degree of 
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polymerisation, molecular weight distribution and topology of the resulting 
polymers.  Chain transfer may occur for every radical at any and all degrees of 
polymerisation and the influence of chain transfer on the average degree of 
polymerisation and on polydispersity carries enormous consequences.  The initiation 
step can be slow compared with propagation due to the inefficient radical formation 
for some initiators.  High concentrations of radical species in solution are 
undesirable because this increases the probability of bimolecular termination.  This 
frequent termination means that there are no polymer chain ends able to continue 
with the propagation process.  Consequently, traditional free radical polymerisation 







Figure 3.4: Reaction steps of a free radical polymerisation.  Where, In = initiator, M 
= monomer, P = polymer, TA = transfer agent, Kd = rate of dissociation, Ki = rate of 
initiation, Kp = rate of polymerisation, Ktc = rate of termination via coupling, Ktd = 
rate of termination via disproportionation, KtrM = rate of transfer to monomer, KtrP = 




3.2.4 Controlled and Living Polymerisation Techniques 
In order to maintain a low concentration of free radicals in solution, (enabling the 
formation of polymers with more complex compositions) techniques allowing for the 
reversible deactivation of free radicals have been developed.  Living/controlled 
polymerisations may include slow initiation, reversible formation of species with 
various activities and lifetimes, reversible formation of inactive species, and/or 
reversible transfer. 
Controlled living free radical polymerisations can be divided into several main types; 
stable free radical polymerisation (SFRP); atom transfer radical polymerisation 
(ATRP); nitroxide-mediated polymerisation (NMP) and reversible addition-
fragmentation chain transfer polymerisation (RAFT).
24
 
Living polymerisations must not include irreversible deactivation and irreversible 
transfer.  These controlled free radical polymerisations (CRPs) yield polymers with 
well-defined composition and molecular weights, narrow polydispersities and 
controlled topology and functionality. The criteria for polymerisation to be termed as 
'living' (as defined by Quirk and Lee)
25
 are as follows: 
1. The growth of the chain continues until all the monomer has been used up. 
2. The molecular weight increases proportionally with conversion. 
3. The concentration of the active species is constant regardless of the level of 
conversion. 
4. The polydispersities are low. 
5. The block copolymers are synthesised by sequential monomer addition. 
6.  The polymer chain ends maintain functionality. 
 
3.2.4.1 Reversible Addition-Fragmentation chain Transfer (RAFT) 
Reversible Addition-Fragmentation chain Transfer or RAFT polymerisation is one of 
several living or controlled radical polymerisation techniques.  Other examples being 
atom transfer radical polymerisation (ATRP) and nitroxide-mediated polymerisation 
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(NMP).  RAFT polymerisation was first developed at CSIRO in 1998.
24
 It soon 
became the focus of intensive research, since the method allows synthetic tailoring 
of macromolecules with complex architectures with predetermined molecular 
weights.  RAFT is among the most successful CRP techniques due to its 
applicability to a wide range of monomers.  Exchange reactions in this particular 
technique are very fast which lead to well controlled systems.
26
 The RAFT process 
involves conventional free radical polymerisation in the presence of a suitable chain 
transfer agent (RAFT agent).  Some examples of commonly used RAFT agents 
include thiocarbonylthio compounds such as dithioesters, thiocarbamates, and 
xanthates, which are used to mediate the polymerisation via a reversible chain-
transfer process.  RAFT polymerisation can be applied to a wide range of 
monomers under a large number of experimental conditions, including the 
preparation of water-soluble materials.  As with other controlled radical 
polymerisation techniques, RAFT polymerisations can be performed with 
conditions to favour low polydispersity indices and a predetermined molecular 
weight.
27
 RAFT polymerisation can be used to design polymers of complex 














3.2.5 Reaction Components 
 
3.2.5.1 The RAFT Agent 
The choice of RAFT agent should pay particular attention to the monomer being 
polymerised and the reaction conditions for the polymerisation.  RAFT agents 
typically contain a thiocarbonylthio group (S=C-S) with substituents R and Z that 
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impact the reaction kinetics and the degree of structural control in the 
polymerisation.
30
 Initiation is achieved using conventional thermal, photochemical or 
redox methods and the correct choice of RAFT agent for the monomer and the 
reaction conditions will determine the success of the polymerisation reaction. 
 
 
Figure 3.5: Raft agent 2-phenylprop-2-ylphenyldithioacetate (PPPDTA). 
 
3.2.5.2 Monomers 
One of the main advantages of using RAFT polymerisation over other controlled 
living free radical polymerisation techniques is the compatibility with a wide range 
of monomers.  RAFT polymerisation is compatible with a much wider range of 
monomers than ATRP, from common monomers such as styrene to functioned 
monomers such as acrylic acid and even electron donating monomers such as vinyl 
esters. 
 
3.2.5.3 Reaction Temperatures 
There is an optimum temperature range for each monomer polymerised under RAFT 
conditions which depends on the nature of the monomer as well as the RAFT agent 
used.  The rate of polymerisation increases with the greater temperature due to the 
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increase in the radical propagation rate constant.  The activation energy of 
propagation is higher than the activation energy of radical termination; therefore the 
kp/kt ratio will increase, consequently improving the control over the system.  
However, at higher temperatures, chain transfer and other side reactions become 
more likely, so the optimum temperature range will take this into account.    
 
3.2.5.4 Reaction Time  
The reaction time for a particular polymerisation will have an effect on the molecular 
weight distributions and the polymer architecture.  The rate of propagation will slow 
down as the polymerisation reaches completion; however, any side reactions 
occurring will be independent of the monomer concentration and as such will 
continue at the same rate.  Therefore, continued heating once all the monomer has 
been used is not recommended as it may affect the RAFT functionality, affecting 
block formation. 
 
3.2.5.5 Solvents and Media 
RAFT polymerisations can be carried out in a variety of media, such as in alcohols 
or aqueous solution, although polymerisations can also be carried out in bulk.  The 
main factor to consider is the solubility of the monomer, RAFT agent and initiator in 
the chosen solvent.  RAFT polymerisations are unaffected by the polarity of the 
solvent; successful polymerisations have been carried out in water, short-chain 





3.3 Poly(Oligo(ethylene glycol)methacrylate) POEGMA 
Poly(ethylene glycol) (PEG) is an uncharged, water-soluble, nontoxic, non-
immunogenic polymer and is therefore the most applied synthetic polymer in the 
field of biomedical science.
31
 Monomers composed of a (meth)acrylate moiety 
connected to a short poly(ethylene)glycol (PEG) chain are versatile building-blocks 
for the preparation of 'smart' macromolecules.  Many of these monomers are 
commercial and can be easily polymerized by either anionic, free-radical, or 
controlled radical polymerisation.  The CRP approach allows synthesis of well-
defined PEG-based macromolecular architectures such as amphiphilic block 
copolymers and dense polymer brushes.  Furthermore, the resulting polymers exhibit 
fascinating solution properties in aqueous medium.  Depending on the molecular 
structure of their monomer units, non-linear PEG analogues can be either insoluble 
in water, readily soluble up to 100°C, or thermo-responsive.  Thus, these polymers 
can be used for building a wide variety of modern materials such as biosensors, 
artificial tissues, smart gels for chromatography, and drug carriers.32 
 
 




3.4 Aims and Objectives 
There is a recognized need to create well-defined polymer probes for in vivo and 
clinical PET and SPECT imaging to guide the development of new generation 
polymer therapeutics.  “Polymer therapeutics”, which can be used to describe 
polymeric drugs, polymer drug conjugates, polymeric micelles, polymer protein 
conjugates, and polyplexes, has become an emerging field of interest in both 
chemical and medical sciences over the last four decades.   By introducing small 
radioactive probes into the polymeric system and using nuclear medicine imaging 
techniques such as positron emission tomography (PET) and single photon emission 
computed tomography (SPECT), pharmacokinetics, and distribution of the polymer 
therapeutic can be easily monitored.
33
 
The aim is to synthesise a bifunctional copolymer (POEGMA-co-PAMA) which is 
biocompatible and can be attached to a HYNIC group and subsequently a peptide.  
The first step is to bind HYNIC to the copolymer, if that proves to be successful; a 
target specific receptor such as a short-sequence peptide will be attached.  The aim is 
then to radiolabel the bifunctional copolymer with technetium-99 for SPECT. 
With regards to the therapeutic eff ects of a polymer-based drug carrier system, the 
choice of backbone plays a crucial role.  Essential requirements include 
biodegradability or biocompatibility with final excretion properties.  The polymer 
must be well-defined in order to be developed as a polymer therapeutic.  Fortunately, 
the introduction of living radical polymerisation techniques, such as ATRP and 
RAFT techniques have allowed well-defined polymer structures to become available.  
The RAFT technique off ers access to diff erent polymer architectures and various 
functional groups, for example, imaging moieties or therapeutics can be attached.  
This route allows for preparation of block copolymers of specific composition.33 
Poly(oligo(ethylene glycol)methacrylate) (POEGMA) is chosen as the copolymer 
back bone as it is a biocompatible polymer.
32
 Oligo(ethylene glycol)methacrylates 
(OEGMAs) are easily polymerisable using controlled radical polymerisation 
techniques such as atom transfer radical polymerisation (ATRP) and reversible 
addition-fragmentation chain transfer polymerisation (RAFT).  The controlled 
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radical polymerisation of the OEGMA allows for a broad range of linear (homo, 
random, block), hyperbranched, dendric, and star (co)polymers.
28
 The 
biocompatibility of the oligo(ethylene glycol) (OEG) pendant groups allows 





Figure 3.7: Structure of POEGMA-co-PAMA. 
 
2-aminoethyl methacrylate hydrochloride can be added into the polymer structure as 
a comonomer. This will later allow for the binding of a copolymer to the HYNIC 
derivatives. 
 A suitable coupling strategy is essential since direct labelling of a molecule occurs 
only exceptionally.  A linker must be labelled with the radionuclide of interest under 
conditions compatible with the stability of the labelled molecule; the label should be 
sufficiently stable under in vivo conditions; labelling should not affect the eventual 
specific binding ability of the biomolecule and non-specific interactions of the 
radioconjugate in organism should be as low as possible.  The coupling strategy 
design depends on the character of the radionuclide binding - whether it is covalent 
binding (e.g.  iodine radioisotopes) or chelation (metal ion radioisotopes)
34
 
Once the copolymer POEGMA-co-PAMA has been synthesised it will need to be 
attached to the activated ester form of HYNIC.  Active esters are improved 
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conjugation reagents which are prepared by the action of a dehydrating agent on a 
ligand containing a free carboxylic acid and a hydroxyl on a potential leaving group.  
The active ester reacts cleanly with deprotonated primary amines to form a very 
stable amide bond.  The reaction can be carried out in aqueous conditions or using 
organic solvents.  In this case, the conjugation will be achieved using EDC (1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide hydrochloride) coupling.   
The short-sequence peptide will then be attached.  The aim is to then radiolabel the 
bifunctional copolymer with technetium-99m for SPECT. 
The advantage of attaching the radionuclide to a copolymer is that the number of 
binding sites is increased, making it a viable choice for radiolabelling applications.  
The chances of successfully imaging the point of interest, for example, a cancerous 
tumour where receptors are over-expressed, is therefore increased. 
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3.5 Experimental Section 
3.5.1 Materials  
Azobisisobutyronitrile (AIBN) was purchased from Molekula and used as received.  
Propanol (laboratory reagent grade) and chloroform (laboratory reagent grade) were 
purchased from Fisher and used without further purification.  Aluminium oxide 
(activated, neutral, Brockmann 1, for chromatography, 50-200 µm) was purchased 
from Acros Organics.  Polyoligo(ethylene glycol) methyl ether methacrylate 
(OEGMA) was purchased from Sigma Aldrich; to remove inhibitor OEGMA was 
run down an alumina oxide column.  RAFT agent PPPDTA was synthesised 
according to literature method.
35
 2-aminoethyl methacrylate hydrochloride (AMA) 
(90%) was purchased from Aldrich and was purified by recrystallisation - AMA was 
dissolved in chloroform, filtered to remove insoluble impurities and dried under 
vacuum.   
 








C nuclear magnetic resonance (NMR) spectra were 
recorded using a JEOL ECS-400 spectrometer at 30°C from solutions in CDCl3.    
GPC: Molecular weight characteristics of polymers were estimated relative to 
PMMA standards by gel permeation chromatography (GPC) using a PL-GPC 50 
supplied by Polymer Laboratories Ltd, in conjunction with a refractive index 
detector.   All determinations were carried out at 40°C with tetrahydrofuran (THF) as 
a mobile phase at a flow rate of 1 ml min-1, using a 50 mm x 7.8 mm 10 µm PLgel 




3.5.3 Polymeric Syntheses 
 
3.5.3.1 A typical procedure for the RAFT synthesis of POEGMA with a 
degree of polymerisation (DP) of 50 units is given as follows; 
 
 
Scheme 3.2: Reaction sequence for the preparation of POEGMA. 
 
Poly(ethylene glycol) methyl ether methacrylate (5.0g; 16.7mmol), RAFT agent 2-
phenylprop-2-yl phenyldithioacteate (PPPDTA) (0.0895g; 3.34mmol), AIBN 
(0.6mg; 0.00366mmol) and propanol (5ml) were added to a Schlenk tube.  The 
mixture was degassed through several freeze thaw cycles, sealed under vacuum and 
heated in a constant temperature bath at 70°C for 24 hours.  The reaction mixture 
was exposed to air to stop the reaction.  The product was retrieved by precipitation of 
the reaction mixture into hexane, filtered and dried under vacuum overnight to yield 





H-NMR (399.78 MHz; (CD3)2SO): δ 0.87 (s, e-H) 1.03 (s, e-H), 1.25 (s, e-H), 1.86 
(q, d-H), 3.38 (s, a-H), 3.56 (s, b-H), 3.66 (s, b-H), 3.74 (t, b-H,) 3.56 (s, c-H). 
 
3.5.3.2 A typical procedure for the RAFT synthesis of POEGMA-co-
PAMA with 5% AMA is given as follows; 
Poly(ethylene glycol) methyl ether methacrylate (5.00 g; 16.7 mmol), 2-aminoethyl 
methacrylate hydrochloride (0.138 g), RAFT agent PPPDTA (0.0895 g; 3.34 mmol), 
AIBN (0.6 mg; 0.00366 mmol), deionised water (1 ml) and propanol (4 ml) were 
added to a Schlenk tube.  The mixture was degassed through several freeze thaw 
cycles, sealed under vacuum and heated in a constant temperature bath at 70°C for a 
predetermined time (see table 3.1).  The reaction mixture was exposed to air to stop 
the reaction.  The polymer product was retrieved by precipitation of the reaction 




3.5.3.2 A typical procedure for the RAFT synthesis of POEGMA-co-
PAMA with 10% AMA is given as follows; 
Poly(ethylene glycol) methyl ether methacrylate (5.00 g; 16.7 mmol), 2-aminoethyl 
methacrylate hydrochloride (0.275 g), RAFT agent PPPDTA (0.0895 g; 3.34 mmol), 
AIBN (0.6 mg; 0.00366 mmol), deionised water (1 ml) and propanol (4 ml) were 
added to a Schlenk tube.  The mixture was degassed through several freeze thaw 
cycles, sealed under vacuum and heated in a constant temperature bath at 70°C for a 
predetermined time (see table 3.1).  The reaction mixture was exposed to air to stop 
the reaction.  The polymer product was retrieved by precipitation of the reaction 
mixture into hexane, filtered and dried under vacuum overnight.   
The specific mechanism for the RAFT polymerisation of OEGMA is shown in 
figures 3.3a and 3.3b. The homolytic fission of AIBN is shown resulting in two 
radical initiating species. The radical is then transferred from the initiator to an 
OEGMA monomer unit. This OEGMA monomer radical then combines with the 
RAFT agent allowing for the fragmentation steps to occur. Polymerisation can 
continue through the equilibrium of the active and dormant species until 








Scheme 3.3b: Mechanism for the synthesis of POEGMA by RAFT. 
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3.6 Results and Discussion 
The reason for choosing RAFT as the method of polymerisation for the polymers 
presented in this work is due to its ability to synthesise polymers of controlled 
molecular weights and low polydispersity.  There is an optimum chain length for 
every polymeric application which provides the best results for that particular 
application.  In this case, in vivo studies would indicate which chain length would 
give the ideal transportation and binding.  RAFT is therefore an ideal polymerisation 
technique for the synthesis of predetermined chain-length polymers. 
RAFT agents are not currently commercially available and therefore need to be 
synthesised.  The choice of RAFT agent depends on the monomer being polymerised 
and the reaction conditions for the polymerisation.  2-phenylprop-2-
ylphenyldithioacetate (PPPDTA) (see figure 3.2) was selected as the RAFT agent in 
this work.  This is due to the inclusion of a benzyl Z group which means the radical 
in the RAFT intermediate is in a less stable disulphur alkyl position when compared 
to the direct combination with the aromatic ring.  This leads to a faster rate of 
fragmentation and results in a faster establishment of the RAFT equilibrium.  This 
will allow the RAFT agent to mediate the polymerisations at ambient temperatures.   
The RAFT agent was synthesised by a previous PhD student according to the 
method of Quinn and co-workers.
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The controlled radical polymerisation of OEGMA was performed in aqueous 
environment at 70°C and lead to the formation of the homopolymer POEGMA with 










Table 3.1: Polymers synthesised by RAFT (
a
Measured by GPC). 
 
A low molecular weight distribution (low PDI) – in this case 1.25 – indicates that 
there is little variation between the chain lengths in the polymer.  This is desirable, 
particularly in biomedical applications, as it means that the properties and behaviour 
of the resulting polymer are uniform.  In a polymeric drug delivery system, for 
example, a high PDI would result in the different chain lengths being transported and 
metabolised at different rates.  The low polydispersity also indicated that this method 




































H-NMR was used to analyse the structure of the compound.  It is widely accepted 
that the presence of polymeric groups causes the signals shown on 
1
H-NMR to 
broaden (each monomer is similar to its neighbours and therefore the signals 
overlap) and show less splitting than would be expected for an 
1
H-NMR spectrum of 
a monomer or other non-polymeric compounds.  It is also common to see multiple 
peaks for one signal which is indicative of the tacticity of the polymer.  Tacticity is 
the stereochemical arrangement of the units in the main chain of a polymer  
Chemical shift changes of the different molar constituents of the polymer are caused 
by differences in the stereochemical environment of the polymer chain
37
 - in this 
case the methylene groups along the polymer backbone are not equivalent due to 
differing positions of the CH3 and carbonyl groups. This results in multiple signals 
as opposed to the single signal which would otherwise be predicted.  
In the 
1
H -NMR spectrum of POEGMA the first signal was observed as three broad 
singlet peaks at 0.87ppm, 1.03ppm and 1.25ppm.  This signal represents the  CH3 
protons which are bound to the polymeric back-bone (e-H).  The next signal is 
observed at 1.86ppm which is a quintet, and represents the CH2 protons in the back-
bone of the polymer (d-H).  Further downfield, a signal is observed as two singlet 
peaks at 3.56ppm and 3.66ppm and a triplet at 3.74 ppm.  This signal represents the 
CH2 protons on the side chain of the polymer (b-H).  The final signal is observed at 
4.09 ppm which is a singlet peak.  This signal represents the CH2 group on the side 
chain closest to the ester group on the back-bone of the polymer (c-H).  This 
proximity to the electron withdrawing oxygens on the ester group causes a slight 
chemical shift to a higher ppm.   
End group analysis was not performed due to the absence of a  signal corresponding 
to the aromatic region on the polymer. 
Due to server back ups it has not been possible to obtain the exact integrals of the 
signals at 1.86 ppm and between 1.25 ppm and 0.87 ppm. The spectrum shows that 
the signal at 1.86 ppm is slightly larger than would be expected for the proton ratios 
within the signal assignments. GPC results, however, clearly show that a high 
molecular weight polymer was formed; the reaction mixture became significantly 
more viscous; and the vinyl peaks have conclusively disappeared. In the weight of 
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this overwhelming evidence that POEGMA was formed, the difference in integrals 
was attributed either to an impurity or to starting material left in the polymer after 
the precipitation. 
 
Figure 3.8: Proton NMR Spectra showing the comparison between the OEGMA 
monomer and POEGMA. 
Copolymers of OEGMA with 2-aminoethyl methacrylate (AMA) were also 
synthesised via RAFT polymerisation.   The reaction time and the molar percentage 
of comonomer AMA were varied to investigate the effect on the molecular weight 
parameters of the resulting polymers.   The results of these syntheses are shown in 
Table 3.1.    
It is immediately obvious from these results that the addition of a comonomer 
resulted in increased polydispersity – this could be due to differing reactivity ratios 
between the two monomers.   The polydispersity of 16.11 for PA1 is particularly 
high, meaning this can no longer be described as a ‘living’ polymerisation (for which 
polydispersities must be in the region of 1.5 or below).
25
  This reaction was allowed 
to proceed for 24 hours – in order to determine the level of control over the system, 
PA1 was repeated but stopped after 12 hours (PA2).   This resulted in polymers with 
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similar average molecular weights to PA1 but a significantly narrower weight 
distribution.  This indicated that towards the end of the reaction, not all chains grow 
uniformly.  In order to prevent this from occurring, components of the RAFT 
reaction could be systematically varied (for example, changing the temperature or 
the RAFT agent) to attempt to gain a higher level of control over the polymerisation. 
The addition of AMA to the polymeric chain was with a view to binding the 
copolymer to HYNIC.  As such, increasing the proportion of AMA in the copolymer 
would result in more potential sites at which to bind the HYNIC.   This led to the 
synthesis of PA3 and PA4 (Table 3.1).  The increase in AMA molar percentage 
from 5% to 10% gave polymers of much narrower weight distributions, suggesting 
the control over polymerisation had improved.  For these reactions, however, 
reducing the time from 24 hours to 12 actually gave polymer chains which were 
longer than anticipated.   This is difficult to explain in terms of polymerisation 
kinetics, and indicates that a number of other polymerisations would be needed in 
order to fully understand the system.   Varying parameters such as temperature and 
reaction time could potentially find reaction conditions which maintain the lower 
polydispersities observed in PA3 and PA4, whilst also giving targeted molecular 
weights. 
As both of the monomers used in the copolymer are methacrylates and therefore 
have similar structures, the reactivity ratios of the monomers are likely to be 
comparable. For this reason the polymers obtained during the copolymer are 
presumed to be random copolymers however further detailed NMR analysis would 
be necessary to confirm the presence and proportion of AMA in the copolymer. 
Although the system has not been optimised in this work, the results demonstrate 






3.7 Conclusions and Future Work 
The aim of this chapter was to synthesise a block copolymer with narrow 
polydispersity ((Mw/Mn < 1.5) via a RAFT polymerisation technique that could be 
used to conjugate a HYNIC group.  Poly(oligo(ethylene glycol)methacrylate) 
(POEGMA) was chosen as the back-bone of the copolymer as it is biocompatible.  
Oligo(ethylene glycol)methacrylates (OEGMAs) are easily polymerisable using 
reversible addition-fragmentation chain transfer polymerisation (RAFT).  The 
biocompatibility of the oligo(ethylene glycol) (OEG) pendant groups allows 
POEGMA based materials to be used in the biomedical fields. 
POEGMA was synthesised by RAFT and characterised using 
1
H-NMR 
spectroscopy.  GPC confirmed the polydispersity index of 1.25.  
Future work  may include the synthesis of POEGMA homopolymers of differing 
chain lengths, as well as further syntheses of copolymers under varying reaction 
conditions, such as time and molar percentage of AMA, in order to increase the 
control over the system.  Increasing the molar percentage of AMA may offer 
narrower polydispersities.   
It would be necessary to undertake several reactions under differing conditions and it 
would be interesting to measure the conversion via NMR which would allow the 
plotting of kinetic graphs typical of living systems; by combining data about 
molecular weight with conversion percentages acquired from sampling reactions, 
standard kinetic plots can be obtained.  For living polymerisations these should be 
linear, which would be a valuable addition to this work, hopefully indicating the 
‘living’ nature of the RAFT polymerisations conducted here. 
If the RAFT method was optimised, it would also be useful to synthesise a range of 
different copolymers to investigate the possible binding sites and efficiency of 
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Chapter 4 - Conclusions and Future Work 
 
4.1 Conclusions 
This thesis presents the synthesis of various HYNIC analogues that are capable of 
chelating technetium-99m in order to be attached to an amino acid and incorporated 
into a peptide sequence via solid phase peptide synthesis (SPPS) to image site-
specific targets.  While 6-HYNIC has been widely used, 2-HYNIC has not, and as 
such both of these were used in the synthesis of a number of derivatives.   




C NMR, FT-IR and melting point 
data was obtained for comparison with literature.  Two different HYNIC analogues 
(2-HYNIC and 6-HYNIC) and their BOC-protected forms were successfully 
synthesised in high yields with the aim of binding these to copolymer chains.  The 
syntheses of these compounds are non-trivial and required multiple attempts and 





C-NMR spectra for these reactions have shown to be either 
unsuccessful or inconclusive, demonstrating the limitations of the approach for 
synthesising HYNIC and its analogues.   
6-HYNIC has been synthesised according to a modified prep in 74% yield.  6-Boc-
HYNIC has been synthesised according to a modified prep in 98% yield.  NHS-
HYNIC-BOC has been synthesised according to a modified prep in 98% yield.  2-
HYNIC has been synthesised according to a modified prep in 51% yield.  2-Boc-
HYNIC has been synthesised according to a modified prep in 86% yield.   
This work also presents the synthesis of a bifunctional copolymer (POEGMA-co-
PAMA) which is biocompatible and can be attached to a HYNIC group and 
subsequently a peptide. This copolymer was synthesised using a controlled living 
radical polymerisation technique called Reversible Addition Fragmentation chain 
Transfer (RAFT).  This technique was chosen due to its ability to synthesise 
polymers with predetermined molecular weights of complex architectures whilst 
maintaining control over polydispersity.  Copolymers of varying compositions were 
synthesised and analysed by GPC and NMR.  Poly(oligo(ethylene 
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glycol)methacrylate) (POEGMA) was chosen as the back-bone of the copolymer as 
it is biocompatible.  POEGMA was synthesised by RAFT and characterised using 
1




4.2 Future Work 
2-HYNIC provides and possible promising alternative to 6-HYNIC as a BFC for 
binding with technetium-99m. It would be useful to determine whether 2-HYNIC 
gives analogous results to 6-HYNIC and furthermore if 2-HYNIC offers a better 
profile for some radiopharmaceuticals. As 2-HYNIC has been used very little in the 
literature, a  number of different coligands could be explored in order to improve the 
hydrophilicity and stability of the technetium complex with 2-HYNIC. 
In addition, the RAFT method requires optimisation. The optimised method would 
allow for the copolymer to be labelled with technetium-99m for SPECT, providing 
an alternative bioconjugate synthetic route. 
Future work may also include the synthesis of POEGMA homopolymers of differing 
chain lengths, as well as further syntheses of copolymers under varying reaction 
conditions, such as time and molar percentage of AMA, in order to increase the 
control over the system.  Increasing the molar percentage of AMA may offer 
narrower polydispersities.   
It would be necessary to undertake several reactions under differing conditions and it 
would be interesting to measure the conversion via NMR which would allow the 
plotting of kinetic graphs typical of living systems; by combining data about 
molecular weight with conversion percentages acquired from sampling reactions, 
standard kinetic plots can be obtained.  For living polymerisations these should be 
linear, which would be a valuable addition to this work, hopefully indicating the 
‘living’ nature of the RAFT polymerisations conducted here. 
 
 
